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ABSTRACT 
The process of HIV-1 particle production is a multi-step process directed by the 
viral structural protein Gag. As Gag is the only viral protein required to form virus-like 
particles, it presents a viable target for anti-viral therapeutics of which there are currently 
none.  Although the functions of Gag during the particle assembly process have been well 
characterized, one of the least known parts of the assembly process is how Gag is 
targeted to the site of virus assembly.  
 Two main virus assembly sites have been identified in cells that support HIV-1 
replication: the plasma membrane or multivesicular bodies (MVBs). However the 
mechanism by which Gag is targeted to either of these sites remains unknown. The δ 
subunit of Adaptor Protein Complex 3 has previously been identified as a cellular co-
factor for HIV-1 Gag and was reported to mediate Gag trafficking to MVBs, providing a 
mechanism for Gag targeting to this assembly site. Additionally, AP-3δ was reported to 
be required for HIV-1 production, suggesting that Gag to MVB targeting is also required 
for HIV-1 production. 
The work presented in this thesis further investigates the role of AP-3δ in Gag 
trafficking to MVBs and its role in HIV-1 production in previously unexplored host 
environments. Through the use of RNA interference-mediated depletion of AP-3δ, we 
determined that AP-3δ is dispensible for virus replication in infected HeLa cells, 
chronically infected HeLa-LAV cells and infected primary human monocyte-derived 
macrophages. We concomitantly disrupted AP-3 function by disrupting its association 
with membranes and observed no effect on virus production. Collectively, these results 
 vi 
demonstrate that AP-3δ is not required for HIV-1 replication. However, AP-3δ was 
demonstrated to be required for Gag targeting to MVBs thus presenting a new model for 
the function of AP-3δ in the context of HIV-1 replication. 
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CHAPTER I: INTRODUCTION 
 
1. Human Immunodeficiency Virus Type 1 
1.1. Discovery and Global Impact of AIDS and HIV-1  
Human Immunodeficiency Virus Type 1 (HIV-1), the causative agent of acquired 
immunodeficiency syndrome (AIDS) has been the subject of intense investigation since 
its discovery over 30 years ago. The first reported cases of AIDS in the United States 
(US) were published on June 5, 1981 by the Centers for Disease Control (CDC), 
establishing the beginning of the HIV/AIDS epidemic (1). The CDC report described the 
incidence of Pneumocystis carinii pneumonia (PCP) in five homosexual men between the 
ages of 29 and 36 who were also infected with cytomegalovirus (CMV) as a result of 
sexual transmission, and presented with candidiasis as a result of fungal infection. The 
incidence of PCP in these previously healthy patients was considered to be unusual, as 
PCP was typically only observed in severely immunocompromised individuals. The 
possibility was raised that these individuals exhibited cellular immune dysfunction due to 
a common but unidentified exposure thereby predisposing them to opportunistic 
infections such as PCP and candidiasis. Around this time, it was also reported that there 
was a population of young homosexual men in the US who were infected with CMV and 
suffered from an aggressive form of Kaposi’s Sarcoma, a typically benign but rare form 
of cancer that affects older individuals (181). As the incidence of these opportunistic 
infections and cancers increased, it became apparent that these were symptoms of an 
underlying novel disease that was later named AIDS. Although AIDS was initially 
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thought to afflict only homosexual men, this was dispelled by cases of AIDS in 
intravenous drug users, hemophiliacs, heterosexual men and women, infants and children. 
Shortly after AIDS was identified, three independent groups reported the isolation 
of retroviruses specifically from AIDS or at-risk AIDS patients. In 1983, Luc Montagnier 
and colleagues were the first to isolate the novel virus, which was designated as 
lymphadenopathy-associated virus (LAV) (5). Levy and colleagues isolated a virus which 
was designated as AIDS-Related Virus (ARV) (93), and Gallo and colleagues designated 
the virus they isolated as human T-lymphotrophic virus type III (HTLV-III) (140). 
Among these three investigators, Gallo was the first to establish a causative link between 
the retrovirus, HTLV-III, and AIDS (50). This breakthrough led to the development of a 
commercially available enzyme-linked immunosorbent assay (ELISA) designed to detect 
HTLV-III antibodies in patient sera, providing a diagnostic tool for HIV infection (78). 
As the novel retrovirus that was known to cause AIDS gained more attention from the 
scientific and global community, the need for a new name for the virus became evident, 
as there were three different names (i.e. LAV, HTLV-III, or ARV) associated with the 
virus. Therefore, the International Committee on the Taxonomy of Viruses assigned the 
virus a single name, Human Immunodeficiency Virus, now known as HIV-1 (28).  
HIV-1 is transmitted from an infected to an uninfected individual through the 
exchange of bodily fluids, which primarily occurs as a result of unprotected sexual 
intercourse, blood exposure (ie. intravenous drug use with contaminated needles, blood 
transfusions, organ transplantation), and perinatally (ie. during pregnancy, at birth, or 
breastfeeding) (127). Of these modes of transmission, heterosexual intercourse remains 
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the most prevalent worldwide (156, 166). Once transmission occurs, HIV-1 targets the 
CD4-positive (CD4+) cells of the immune system, which include T-lymphocytes (T 
cells), macrophages, monocytes, and dendritic cells (29). The natural course of HIV-1 
infection in untreated individuals results in a gradual decline in the number of CD4+ T 
cells over time, resulting in the progression to AIDS, and eventually, death. HIV-1 
infection begins with the acute phase, which is characterized by exponential viral 
replication and massive depletion of CD4+ T cells, particularly in the gut associated 
lymphoid tissue (GALT) (15, 103). Over time, the immune system mounts a response 
through HIV-specific CD8+ cytotoxic T cell-mediated destruction of HIV-infected cells 
(13, 60) and anti-HIV neutralizing antibodies (65), resulting in the stabilization of the 
viral load. During this period, circulating CD4+ T cells are able to recover temporarily. 
The next stage is clinical latency, a period that can last between 2-10 years, and is 
characterized by low levels of viral replication and asymptomatic presentation (127). The 
inability of the immune system to control the virus however, promotes the gradual 
decline in CD4+ T cells, and leads to the diagnosis of AIDS when CD4+T cell counts fall 
below 200 cells/mL. At this stage, infected individuals are severely immunocompromised 
and become susceptible to opportunistic infections that are ultimately lethal. (128) 
(Figure 1-1).  
To date, HIV has claimed the lives of more than 25 million people and infected an 
estimated 60 million people worldwide (165). In 2009, the global estimate of people 
living with HIV was reported to be 34 million, with a newly infected population of 2.7  
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Figure 1-1. The stages of HIV-1 infection.  
In the acute stage, rapid viral replication reaches a peak viral load, followed by 
stabilization (red line, top), as cytotoxic CD8+T cells (blue line, bottom) and neutralizing 
anti-HIV antibodies develop (yellow line, bottom). Massive depletion of GALT (closed 
circles, bottom) and peripheral (green line, bottom) CD4+T cells occurs, with a gradual 
recovery of peripheral CD4+T cells due to immune system-mediated stabilization of viral 
replication. In the asymptomatic or chronic stage, viral load remains stable, as do 
CD8+CTLs, neutralizing antibodies, and peripheral CD4+T cells, while CD4+T cells in 
the GALT remain depleted. Risk of transmission is lower than in the acute stage, but viral 
diversity is increased. As viral diversity increase, viral replication increases, resulting in 
peripheral CD4+T cell decline and progression to AIDS, when CD4+T cell counts fall 
below 200 cells/mL (gray line). Adapted from Simon et al. (Lancet 2006). 
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million, as well as 1.8 million AIDS-associated deaths (166). The HIV/AIDS pandemic 
has been particularly devastating to the population of sub-Saharan Africa, where the 
number of people living with HIV is approximately 67% of the 2010 global estimate 
(166). However, the sub-Saharan African countries with the largest epidemics have 
demonstrated stabilization in the prevalence of HIV-1infected individuals, a decline in 
the number of people newly infected with HIV, and a decline in the number of AIDS-
related deaths over the past 10 years. This decline in incidence and death rates has been 
greatly attributed to the increased use and accessibility of anti-viral therapies (166). The 
development of effective therapeutics is a direct consequence of the significant scientific 
advancements that have been made in the field of HIV research over the past 30 years. 
However, without a cure or vaccine, the AIDS pandemic will continue to persist. 
Therefore, continued investigation of HIV and its pathogenesis is imperative to promote 
the scientific breakthroughs needed for the development of novel therapeutics and 
eventually a cure.  
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Figure 1-2. Global representation of the number of people infected with HIV in 
2009. Adapted from The UNAIDS Report On The Global AIDS Epidemic:2010 UNAIDS 
Global Report. 
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1.2. HIV-1 Genome and Viral Proteins 
Genome 
HIV-1 is an enveloped positive single-stranded RNA virus belonging to the 
lentivirus family of retroviruses. It is classified as a retrovirus due to its use of reverse 
transcription to convert its RNA genome into DNA. Its further characterization as a 
lentivirus, derived from the Latin term “lente” meaning slow, is attributable to its long 
incubation period in the host and its ability to infect non-dividing cells. The HIV-1 
genome is comprised of long terminal repeat regions (LTR) at its 5’ and 3’ termini ends 
and nine overlapping open reading frames: gag, pol, env, tat, rev, vif, vpr, vpu, and nef 
(Fig.1-3), which generate 15 viral proteins (46) as a result of alternative splicing, 
ribosomal frameshifting, and protease-mediated cleavage of polyprotein precursors.  
Each virion contains two copies of positive-sense, single-stranded RNA of 
approximately 9.2 kilobases (kb) in length, referred to as genomic RNA (gRNA). Shortly 
after infection of the host cell, the single-stranded RNA genome is converted into double-
stranded proviral DNA by reverse transcriptase. As a result of reverse transcription, a 
segment of each LTR is duplicated and added to each end of the proviral DNA, extending 
its total length to approximately 9.8 kb. The proviral DNA is integrated into the host 
genome and undergoes cellular RNA Polymerase II (Pol II)-mediated transcription, 
thereby generating gRNA that is capped and polyadenylated (24, 26). Genomic RNA 
contains many cis-acting elements that are required for different functions during viral 
replication, including: (1) the TAR element that is required for Tat-mediated  
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Figure 1-3. Schematic representation of the HIV-1 genome and the structure of a 
mature HIV-1 virion. Frankel and Young. Annu. Rev. Biochem. (1998) 
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transcription elongation; (2) the primer binding site that is required for tRNALys3 binding 
to initiate reverse transcription; the major splice donor sequence; (3) the packaging signal 
(Ψ) that is required for gRNA encapsidation into nascent virus particles; (4) the 
dimerization site that is required for the incorporation of dimerized gRNA; (5) the major 
splice donor site that is used to generate all spliced viral mRNAs; (6) the slippery 
sequence and the frameshift stimulatory signal that are required for the -1 ribosomal 
frameshift that occurs during the translation of Gag to generate the Gag-Pol precursor; (7) 
a central and 3’ polypurine tract that is required for plus-strand proviral DNA synthesis 
during reverse transcription; (8) the Rev-Response Element (RRE) that is required for 
Rev-mediated export of unspliced viral RNAs; (9) the splice acceptor sites that are 
required the generation of subgenomic viral mRNAs; and (10) the 3’ polyadenylation 
signal, which is required for polyadenylation of the 3’ end of gRNA (reviewed in (46)). 
Viral RNAs are unspliced, partially spliced, or fully spliced, to generate the viral 
transcripts required for the synthesis of the nine viral genes. The nine viral gene products 
are organized into four groups: structural, enzymatic, regulatory, and accessory. 
 
The Structural Proteins 
The translation products Gag and Env comprise the structural proteins. The Gag 
(group-specific antigen) protein, encoded by the gag gene, directs particle production and 
provides the structural architecture for the virus. Gag is translated from gRNA on free 
cytoplasmic ribosomes, resulting in the synthesis of a 55 kD polyprotein precursor known 
as Pr55Gag (47). Gag is comprised of four domains: matrix (MA/p17), capsid (CA/p24), 
 10 
nucleocapsid (NC/p7), p6, and the spacer peptides: SP1 and SP2. During the final stage 
of virion production, Gag undergoes protease-mediated cleavage at the junction of each 
domain resulting in individually processed mature forms of each domain. MA is 
positioned at the N-terminus of Gag and is required for targeting Gag and Gag-Pol to the 
plasma membrane through an N-terminal myristate and a highly basic region (HBR) 
located within the first 31 residues (91, 159). During virus assembly, MA has been 
implicated in facilitating the incorporation of Env into nascent virions (99). Within a 
mature virion, mature MA lines the inner surface of the virus particle and is in direct 
contact with the viral membrane. Following infection, mature MA is associated with the 
pre-integration complex (PIC) and contributes to PIC entry into the nucleus through its 
nuclear localization signal (NLS) (18, 168). The next domain of Gag is CA, which 
mediates Gag:Gag and Gag:Gag-Pol interactions required for virus assembly that are 
mediated by its C-terminal domain (51, 70). Within a mature virion, mature CA forms a 
conically shaped shell around gRNA and additional viral proteins (54). Following 
infection, mature CA undergoes an uncoating process required for infectivity that is 
mediated by the interaction between its N-terminal domain and the cellular factor 
cyclophilin A (96). The next domain is NC, which facilitates gRNA incorporation into 
virions through its two zinc-finger motifs and mediates Gag multimerization (30, 152). 
Within a mature virion, mature NC is tightly associated with gRNA inside the CA core 
(46). Following infection, mature NC acts as a nucleic acid chaperone in the post-entry 
steps of reverse transcription and integration, which enhances the efficiencies of these 
processes (19, 22, 64, 71). The final domain is p6, which mediates Vpr incorporation into 
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the nascent particle (129), and recruits the ESCRT (endosomal sorting complex required 
for transport)-associated components, Tsg101 and Alix, through interactions with its late 
domains, Pro-Thr-Ala-Pro (PTAP) and Tyr-Pro-Xn-Leu (YPXnL), respectively, to 
facilitate the pinching off of fully assembled virus particles from the cell surface (161, 
162).  
The env gene encodes the Env protein, which is required for virus entry into the 
target cell. Env is translated from partially spliced bicistronic vpu/env mRNA in the 
rough endoplasmic reticulum (ER) and is synthesized as the precursor protein, gp160 
(49). The gp160 precursor undergoes co-translational glycosylation and intramolecular 
di-sulfide bond formation, which promotes its trimerization. Following its modification in 
the ER, gp160 is transported to the Golgi apparatus, where it undergoes further 
modification of its glycosylated side chains and is cleaved by the cellular protease, furin 
or a furin-like enzyme, into gp120 and gp41 (176). Following cleavage, gp120 and gp41 
form a non-covalent interaction and are trafficked together from the Golgi to the cell 
surface, through the secretory pathway, which promotes their incorporation into nascent 
virions (48). Viral attachment to the host cell is mediated by binding of surface protein, 
gp120, to the target cell receptor, CD4, triggering a conformational change in gp120 (14). 
This conformational change facilitates its interaction with the cellular co-receptor CCR5, 
or CXCR4 (35). Upon gp120 binding to CD4 and CCR5 or CXCR4, gp41 undergoes a  
conformational change, which brings the cellular viral membranes together until fusion of  
the two membranes occurs (36). Following fusion, the viral contents enter the cell and the 
HIV-1 replication cycle continues.    
 12 
The Enzymatic Proteins 
The pol gene, which encodes the enzymatic proteins: protease (PR), reverse 
transcriptase (RT), and integrase (IN). Similar to Gag, pol is synthesized as a precursor, 
Pr160Gag-Pol or Gag-Pol, and is translated from gRNA. Unlike Gag, however, Gag-Pol is 
translated by a unique mechanism that is dictated by -1 ribosomal frameshifting (42). 
During Gag translation, the ribosome occasionally stalls after encountering the slippery 
sequence and the frameshift stimulatory signal that are located near the junction of the 
gag and pol genes. As a result, -1 frameshift occurs, which allows translation to proceed 
downstream of the gag termination codon, until the pol termination codon is reached. 
This mechanism for translation ensures that Gag-Pol is produced in a 1:20 ratio to Gag 
(48). Gag-Pol is incorporated into virions and during or shortly after virus release, PR 
cleaves itself from Gag-Pol and subsequently cleaves the junctions between the domains 
of Gag and Gag-Pol generating MA, CA, SP1, NC, SP2, p6 from Gag, and PR, RT, IN 
from Gag-Pol. This process results in a dramatic rearrangement of the virion interior and 
drives viral maturation, and is required for viral infectivity (84, 87). The RT enzyme is an 
RNA-dependent DNA polymerase that is required for the reverse transcription of single-
stranded RNA genome into double-stranded proviral DNA. As a result of its lack of 
exonucleolytic proofreading activity, RT is highly error-prone, which enhances the 
genetic diversity of the virus and allows it to evade the cellular immune system (141). 
The IN enzyme catalyzes the integration of proviral DNA into the host genome by for 
integration into the host genome by processing its 3’ ends of proviral DNA to generate 5’ 
overhang (4). Following nuclear import of the PIC, IN catalyzes the staggered cleavage 
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of the host chromosomal DNA in a sequence-independent manner. The recessed 3’ ends 
of the proviral DNA are joined to the 5’ overhangs of the host DNA in a process known 
as strand transfer. Following integration, the cellular repair machinery fills in the gaps 
resulting from the strand transfer, which completes the integration process.  
 
The Regulatory Proteins 
The regulatory proteins Tat and Rev regulate viral gene expression at different 
stages and are required for viral replication. The Tat protein is encoded by two exons of 
the tat gene and is required for RNA Polymerase II (Pol II)-mediated transcription 
elongation, as its absence results in the synthesis of transcripts that are prematurely 
terminated. Upon binding cyclin T/CDK9 complex (positive transcription elongation 
factor b, pTEFb) through its activation domain, Tat undergoes a conformational change 
which increases its affinity for the TAR RNA element present within the first 59 
nucleotides of all viral transcripts (77). After Tat binds to TAR, cyclin T/CDK9 are 
recruited to the Tat/TAR complex and CDK9 hyper-phosphorylates the C-terminal 
domain of Pol II, which promotes Pol II transcription elongation and results in the 
synthesis of complete transcripts (77). 
The Rev protein is encoded by two exons of the rev gene. Rev contains an 
arginine-rich domain that is required for RNA binding and serves as nuclear localization 
signal (NLS) and is flanked by two oligomerization domains (97). It also contains a 
leucine-rich nuclear export signal (NES), which promotes its nuclear export (97). The 
primary function of Rev is to facilitate the nuclear export of unspliced and partially 
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unspliced viral RNAs, and this is mediated through its interaction with the RRE, which is 
present on these RNAs (98). As Rev contains both an NLS and an NES, it acts as a 
shuttling protein to continuously export viral RNAs and re-enter the nucleus to repeat the 
process. Nucleo-cytoplasmic export of Rev is facilitated by its use the CRM1 export 
pathway instead of the more widely used TAP (Tip-associated protein) mRNA export 
pathway, which is thought to allow unspliced RNAs to evade the splicing machinery 
(45).  
 
The Accessory Proteins 
 The accessory proteins are Vif, Vpr, Vpu, and Nef, which were originally shown 
to be dispensible for HIV-1 replication in vitro, but their requirement for efficient virus 
replication in vivo was later established. The Vif protein is encoded by the vif gene and is 
incorporated into virus particles. Vif is not required for virus production, however, it 
plays a role in viral infectivity. The main function of Vif is to promote the degradation of 
the anti-viral cellular factor, APOBEC3G (apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G), a cytidine deaminase enzyme that interferes with HIV-1 
reverse transcription by inhibiting tRNALys3 priming and by deaminating dC to dU in 
minus strand viral cDNA during reverse transcription (63, 101). Vif counteracts 
APOBEC3G by promotes its polyubiquitination which subsequently targets it to the 
proteasome for degradation (104).  
 The Vpr protein is encoded by the vpr gene and is incorporated into virus 
particles. Vpr contains two NLSs that mediate the nuclear import of the PIC by through 
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direct binding to the nuclear import factor, karyopherin α, which enhances its affinity for 
NLSs (139). Another function of Vpr is its ability to arrest cells in the G2 phase of the 
cell cycle, which is thought to increase HIV-1 LTR-driven transcription (56). Vpr has 
also been implicated in enhancing the fidelity of reverse transcription through its 
interaction with UNG2 (uracil DNA glycosylase), an enzyme that specifically removes 
the RNA base uracil from DNA as a result of its misincorporation or cytosine 
deamination (102).  
 Vpu protein is translated from a bicistronic vpu/env mRNA and directly targets 
the cytoplasmic tail of newly synthesized CD4 in the ER to the proteasome for 
degradation (153, 177). The involvement of Vpu in particle release has been 
demonstrated through the observation that Vpu-deficient viruses were retained at the 
plasma membrane in intracellular vesicles (86). This suggested that Vpu plays a role in 
virus release and prevents endocytosis of nascent virions from the plasma membrane 
(107). However the mechanism by which this occurred was not known until recent 
studies demonstrated that the release defect was caused by the cellular factor, Tetherin, a 
transmembrane protein which inserts its N-terminal extracellular domain into the 
membranes of nascent virions while remaining attached to the plasma membrane, thereby 
tethering the virion to the cell surface (108, 133). The inhibitory function of Tetherin is 
antagonized by Vpu, which targets Tetherin to the proteasome for its degradation (100).  
 The Nef protein is encoded by the nef gene and is incorporated into virus 
particles. Similar to Gag, Nef has a bipartite membrane signal comprised of on N-
terminal myristate and an N-terminal patch of basic residues (172). One of the main 
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functions of Nef is to downregulate CD4 from the cell surface through its interaction with 
the di-leucine motif present in the cytoplasmic tail of CD4 and Adapter Protein Complex-
2. This interaction induces the endocytosis of CD4 and Nef, and results in CD4 and Nef 
internalization in endosomes. In the endosome, Nef promotes the interaction between 
CD4 and the β subunit of the COP I vesicle coat protein, β-COP, which targets CD4 to 
the lysosome for degradation (137). In addition to its role in CD4 downregulation, Nef 
also downregulates MHC (major histocompatibility complex) class I, which further 
demonstrates its function as an immune modulator (27).  
 
1.3. The HIV-1 Replication Cycle 
The HIV-1 replication cycle is a complex, multi-part process that begins with 
viral infection of the target cell and ends with the production of mature, infectious virus 
particles (reviewed in (46, 47)) (Fig. 1-4). The early stage of the viral life cycle begins 
with viral attachment to the target cell through an interaction between gp120 and the 
cellular receptor CD4 and the chemokine co-receptors CCR5 or CXCR4. Upon CD4 and 
co-receptor binding, gp120 and gp41 undergo a conformational change resulting in viral 
and cellular membrane fusion. Following fusion the viral contents are released into the 
cytoplasm of the infected cell. The CA core undergoes a process of uncoating that 
liberates its internal contents: genomic RNA, NC, RT, IN, and Vpr. Uncoating promotes 
the formation of the reverse transcription complex (RTC), in which gRNA is reverse 
transcribed by RT into double-stranded proviral DNA. Completion of reverse 
transcription leads to the formation of the pre-integration complex (PIC), a nucleoprotein  
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Figure 1-4. The HIV-1 replication cycle. The HIV-1 replication cycle is divided into 
early (pre-integration) and late stages (post-integration). The early stage is comprised of 
viral attachment, fusion, viral entry, uncoating, reverse transcription of the viral genomic 
RNA into proviral DNA, import of the proviral DNA and associated viral proteins into 
the nucleus, and integration of the proviral DNA into the host genome. The late stage is 
comprised of viral gene transcription, nuclear export of viral RNAs, viral RNA 
translation, virus assembly, budding, viral egress from the target cell, and viral 
maturation. D’Souza and Summers. Nat. Rev. Microbiol. (2005) 
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complex comprised of proviral DNA, MA, RT, IN, and Vpr (160). The PIC translocates 
from the cytoplasm into the nucleus through the nuclear localization signals (NLS) 
present in MA and IN, as well as Vpr-mediated enhancement of NLS binding to the 
nuclear import factor, karyopherin α (139). Following nuclear entry, the proviral DNA is 
integrated into the host genome by IN and undergoes Pol-II-mediated transcription, 
which requires Tat for transcription elongation. RRE-containing unspliced and partially 
spliced viral RNAs are exported by Rev into the cytoplasm through the CRM1 pathway, 
and fully spliced viral RNAs are exported through the TAP pathway. Following nuclear 
export, viral RNAs are translated, and the viral components required for infectious 
particle production localize to the site of virus assembly and are incorporated into 
progeny virions. Gag dictates these late events in the viral life cycle through the function 
of its domains. MA targets and binds Gag to the plasma membrane, where assembly 
occurs, and also facilitates Env incorporation into the virion. CA, SP2, and NC mediate 
Gag:Gag interactions which are required to form the particle and facilitates Gag-Pol 
incorporation. NC incorporates gRNA into the particle by binding to the Ψ of gRNA. The 
p6 domain incorporates Vpr into the nascent virion and also recruits the ESCRT 
machinery, which is required for virus budding and pinching off from the membrane. 
Either during or immediately after virus release, PR cleaves the polyproteins, resulting in 
viral maturation and a dramatic rearrangement of the viral interior. Following maturation, 
virus particles are competent to infect and replicate in new target cells, thus completing 
the viral replication cycle.  
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The resulting virus is roughly spherical in shape and is approximately 130 nm in 
diameter (21). At the center of the virion is a gRNA dimer, surrounded by NC, RT, IN, 
and Vpr, which are all contained within a conically-shaped protein core comprised of CA 
monomers. PR is present in the space between the core and an outer layer comprised of 
MA monomers. The layer of MA monomers directly interacts with the lipid bilayer, the 
outermost layer of the virus, which is acquired after viral budding from the host cell 
membrane. The virion surface is studded with trimeric glycoprotein spikes comprised of 
gp120 and gp41.  
 
2. HIV-1 Particle Production 
2.1. Role of Gag 
Successful completion of the HIV-1 replication cycle is marked by the production 
of infectious virus particles, which ensures the continued propagation of the virus. The 
viral structural protein, Gag, drives virus production and is necessary and sufficient for 
this process. Although Gag relies on host factors for virus production, it is the only viral 
protein required for this process, as its expression alone results in the formation of virus-
like particles (55, 155). Gag mediates virus production through a complex series of steps 
directed by its subdomains that involve Gag targeting to the site of assembly, Gag 
binding to cellular membranes, Gag multimerization, Gag-mediated virus budding and 
release (170) (Fig. 1-5).  
The MA domain targets and binds Gag to membranes through a bipartite signal 
consisting of an N-terminal myristate, which is added during translation, and a highly  
 20 
 
 
 
 
Figure 1-5. Schematic representation of HIV-1 Gag and HIV-1 Gag domains.  
(A) Organization of the domains within the Gag polyprotein. (B) Domains of Gag and 
their key features. Freed. Virology. (1998) 
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basic region (HBR) spanning residues 14-31 (27). Inhibition of MA-mediated membrane 
binding of Gag through disruption of the myristate modification and mutation of the HBR 
has been shown to also inhibit virus production (122, 182, 183). The CA and NC domains 
promote the Gag-Gag interactions that contribute to the overall architecture of the virus 
particle, which contains approximately 5000 copies of Gag (16). NC additionally 
promotes multimerization through its interaction with gRNA, which serves as a scaffold 
for Gag multimerization (88). In addition, Gag multimerization has been suggested to 
enhance Gag binding to membranes by promoting the exposure of myristate on MA (66, 
163). During the viral assembly process, Gag-Pol, gRNA, Env (gp120/gp41), Vif, Vpr, 
and Nef, are incorporated into the developing virus particle (46). Finally, the C-terminal 
p6 domain recruits the ESCRT (endosomal sorting complex required for transport) 
through its interaction with the ESCRT components Tsg101 and ALIX, initiating the 
final stage of viral budding and release (161, 162).  
 
2.2. Sites of Virus Production 
Plasma membrane 
The plasma membrane has been demonstrated to be the predominant site of virus 
production in all cell types. Although the cell interior is comprised of a multitude of 
organelles and compartments bound by membranes of various compositions, Gag has 
developed the capability of navigating the cell interior from the site of its translation and 
specifically bind to the plasma membrane through its N-terminal myrsitate and HBR. 
Recent studies have shown that plasma membrane specificity is mediated by the 
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interaction of the basic residues within the HBR of MA and phosphatidylinositol (4, 5) 
bisphosphate (PI(4,5)P2), an acidic phospholipid that is enriched in the inner leaflet of 
the plasma membrane (117). Mutating the basic residues of the HBR results in reduced 
Gag-membrane binding as well as aberrant localization to intracellular compartments. 
Myristate exposure is triggered by Gag multimerization, but it is also triggered by the 
interaction of the HBR with PI(4,5)P2, which enhances Gag binding to the plasma 
membrane (27). Depletion of PI(4,5)P2 through the overexpression of 
polyphosphoinositide 5-phosphatase IV (5ptaseIV) or a constitutively active Arf6 mutant, 
Arf6/Q67L, disrupts Gag association with the plasma membrane and instead results in the 
targeting of Gag to multivesicular bodies (118). In the presence of the PI(4,5)P2 
inhibitors, particle production is severely compromised, indicating that Gag localization 
to the plasma membrane is essential for virus production.  
In addition to PI(4,5)P2, lipid rafts and tetraspanin-enriched microdomains (TEM) 
have also been demonstrated to promote virus assembly at the plasma membrane (116). 
Lipid rafts are microdomains enriched in cholesterol and glycosphingolipids and contain 
specific markers that are found on the membranes of virus particles, suggesting that virus 
production takes place at these sites (2, 111). In addition, Gag has been shown to co-
localize and co-fractionate with lipid raft markers providing further evidence for the 
involvement of lipid rafts in virus assembly (69, 111, 121). Furthermore, Gag and Env 
been shown to associate with detergent resistant membranes, which are thought to be 
derivatives of lipid rafts (11).  
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Tetraspanins represent a large family of proteins comprised of four 
transmembrane domains and are expressed on the cell surface (94). These transmembrane 
proteins can form heterogeneous clusters at the plasma membrane known as TEMs (94). 
TEM involvement in virus assembly has been demonstrated by microscopy studies in 
which Gag localized to TEMs comprised of the tetraspanins CD9, CD63, CD81, and 
CD82 (116). In addition, Env co-localized with Gag at these TEMs providing evidence 
that virus assembly takes place at these microdomains (116). Furthermore, tetraspanins 
are incorporated into the membranes of virions (25, 79, 110, 132) and have been 
observed at plasma membrane-derived intracellular virus-containing compartments (34), 
strongly suggesting that TEMs are sites of virus assembly.  
 
Multivesicular bodies 
 Multivesicular bodies (MVB) are membrane-bound organelles that are derived 
from early endosomes and contain a number of intraluminal vesicles (ILV) as a result of 
inward budding from their limiting (outer) membrane (138). The process of inward 
budding and ILV formation is mediated by the ESCRT complexes and their related 
components (178). Proteins that reside within the ILVs of MVBs are typically mono-
ubiquitinated and are destined for lysosomal degradation. The delivery of MVB-
containing cargo to lysosomes is mediated by the fusion of the two compartments (138). 
In addition to fusion-mediated delivery to lysosomes, MVBs can also deliver their 
contents to the extracellular space as exosomes, upon fusion with the plasma membrane 
(167). Virus assembly has been demonstrated to occur in MVBs in multiple cell types, 
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but is more apparent in macrophages. Early electron microscopy (EM) studies 
demonstrated that in macrophages, HIV-1 production predominantly occurs in 
intracellular compartments identified as MVBs, according to their co-localization with 
MVB markers CD63 and LAMP-1 (110, 120, 126, 132, 144). In addition, MVB-derived 
viruses are infectious, suggesting that MVBs are productive sites for virus assembly and 
budding in macrophages (110, 132). Viral egress from these compartments has been 
suggested to occur through exocytosis, which has been supported by EM studies as well 
as the demonstration that extracellular virions immunoprecipitate with MVB marker-
specific antibodies (110, 132). The discovery that HIV-1 uses the ESCRT machinery to 
facilitate its budding and release has also provided support for the proposal that MVBs 
are bona fide sites for virus production, due to the link between MVB biogenesis and the 
function of the ESCRT machinery (53). Virus production has also been demonstrated to 
occur in the MVBs of non-macrophage cell types such as T-cells, HeLa cells, and COS 
cells previously understood to promote virus production only at the plasma membrane 
(53, 115, 154). In addition, MVB-derived viruses in these cell types were shown to be 
infectious (61). Collectively, these results demonstrate that MVBs are sites of virus 
assembly, however, it is controversial whether they are productive sites for HIV-1 
replication.  
 
3. Adaptor Protein Complex-3  
3.1. Adaptor Protein Complexes 
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Adaptor Protein Complexes (AP) coat vesicles and mediate the transport of 
proteins from a donor membrane to a target membrane. To date, five APs have been 
identified: AP-1, AP-2, AP-3, AP-4, and AP-5 (68). The first four AP complexes are 
ubiquitously expressed and have been well characterized (12, 106), while AP-5 was 
recently identified and awaits further characterization. APs are made up of two large 
~100-160 kD subunits (γ/β1, α/β2, δ/β3, ε/β-4), one medium ~50 kD subunit (µ1-4), and 
one small ~20 kD subunit (σ1-4) (reviewed in (12, 106)). Each subunit or adaptin has a 
separate function. The β1−3 subunits contain a clathrin-binding motif known as the 
clathrin box, which facilitates clathrin recruitment. β4 lacks a clathrin box and therefore 
does not interact with clathrin. The other large subunit of each AP is responsible for 
binding the complex to the target membrane. The µ subunit is responsible for selecting 
cargo through its recognition and interaction with tyrosine-based sorting signals (YXXΦ, 
X is any amino acid, and Φ is any amino acid with a bulky hydrophobic side chain) or 
dileucine motifs (D/EXXXLL/I, where the first amino acid can be D or E, and X is any 
amino acid, and the last amino acid can be L or I) that are present in the cytoplasmic 
domains of the cargo. The σ subunit is responsible for stabilization of the complex. The 
APs assemble into a structure that has been reported to resemble the head of “Mickey 
Mouse,” due to its brick-like “head,” from which two “ears” protrude, and are connected 
by flexible hinges. The “head” region is comprised of the amino-terminal domains of the 
two large subunits, medium subunit, and small subunit, and the two “ears” are comprised 
of the carboxy-terminal domains of the large subunits (67, 130, 145).  
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 3.2 Identification of AP-3 
AP-3 was initially identified as a result of two studies (157, 158) conducted with 
proteins that were identified by two different groups: β-neuronal adaptin-like protein (β-
NAP) (109) and p47 (136), which shared ~30% homology with the β and µ subunits of 
AP-1 and AP-2, respectively (32, 109, 136, 157, 158). The existence of p47 in non-
neuronal (p47A) and neuronal (p47B) forms prompted a search for a non-neuronal form 
of β-NAP, which was identified through a search of the human expressed sequence tag 
(EST) database. β-NAP and p47 complexed with one another and could be recruited from 
the cytosol onto membranes in vitro. This complex immunoprecipitated with two other 
proteins: a ~160 kD protein, p160, and a ~25 kD protein, p25, suggesting that the 
complex was a heterotetramer (158). As predicted, p160 and p25 were found to be 
homologous with the γ/α and σ1/σ2 subunits of AP-1 and AP-2, respectively. These 
findings ultimately led to the identification of a third novel adaptor protein complex, 
which was aptly named AP-3. Non-neuronal and neuronal β-NAPs were renamed β3A 
and β3B, respectively; p47A and p47B were renamed µ3A and µ3B; p160 was named δ; 
and p25, which was identified as two isoforms was named σ3A and σ3B, although both 
forms are ubiquitously expressed (32, 158). The identified AP-3 complex was the 
neuronal form, while subsequent studies identified the ubiquitous form of the complex 
(32). The ubiquitous and neuronal forms of AP-3 have been designated as AP-3A and 
AP-3B, respectively, in this thesis, only the ubiquitous form will be addressed and will be 
referred to as AP-3.  
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3.3 Function and Regulation 
Function 
The cellular function of AP-3 is to transport transmembrane proteins to lysosomes 
or lysosome-related organelles from early endosomes (130) or the trans-Golgi network 
(32, 157, 158) (Fig.1-6). There are two distinct lysosomal trafficking pathways, and both 
are used by AP-3. In the direct pathway, AP-3 traffics newly synthesized LMPs from the 
trans-Golgi network (TGN) to the late endosome/MVB, which subsequently fuses with 
the lysosome for delivery of the LMPs. In the indirect pathway, newly synthesized LMPs 
are first transported directly to the plasma membrane and are subsequently endocytosed 
and are localized to the early sorting endosome (73). AP-3 traffics the LMPs from the 
early endosomes to MVBs, and the LMPs are delivered to the lysosome following its 
fusion with the MVB. The µ3 subunit selects AP-3-directed cargo through its recognition 
of tyrosine motifs or dileucine motifs within the cytoplasmic tails of the cargo (106).  
The current understanding of AP-3 function in trafficking specific lysosomal 
membrane proteins to lysosomes has been made possible through AP-3 subunit deletion 
studies in yeast, and the existence of naturally occurring AP-3 subunit mutations in 
Drosophila, murines, and humans (145). In Drosophila, four mutants: garnet, ruby, 
carmine, and orange, which exhibit altered eye-color pigment have naturally occurring 
mutations in the genes that encode the δ, β3, µ3, and σ3 subunits, respectively (145). 
Further investigation of the garnet mutant revealed a reduction in the number of red and 
brown pigment-containing pigment granules of the eye (124). This suggested a role for 
AP-3 in the biogenesis of pigment granules, which are lysosome-related organelles 
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(LRO). Further insight into AP-3 function has been attributed to studies of the mocha 
mouse, a murine mutant that does not express the δ subunit due to a null mutation in the 
δ-encoding gene (83). As a consequence, the remaining subunits are degraded and 
therefore the mice lack the entire complex (131). These observations demonstrated that 
the subunits only exist in the context of the complex. As a consequence of AP-3 
deficiency, mocha mice exhibit decreased levels of renal lysosomal enzymes in the urine, 
hypopigmentation of the eye and coat, prolonged bleeding times, as well as neurological 
defects (83). These symptoms are attributable to defects in protein trafficking to 
lysosomes, melanosomes, platelet dense granules, and synaptic vesicles, with the latter 
four compartments representing LROs.  
In humans, a mutation in the β3A subunit causes a rare disorder known as 
Hermansky-Pudlak Syndrome Type 2, which results in hypopigmentation of the eye, hair, 
and skin, platelet dysfunction, and immunodeficiency resulting from neutropenia and 
cytotoxic T-lymphocyte dysfunction (72, 174). Cellular studies have also shown that the 
absence of AP-3 results in the re-routing of the most abundant lysosomal membrane 
proteins: lysosome associated membrane proteins 1 and 2 (LAMP-1 and LAMP-2), 
lysosomal integral membrane protein 2 (LIMP-2), and tetrapanin CD63 to the PM (150). 
Taken together, these observations have strongly implicated AP-3 function in the 
trafficking of cargo destined for lysosomes and lysosome-related organelles.  
Although AP-3 is often referred to as a clathrin adaptor, the role of clathrin in AP-
3 function is controversial. Initial studies that led to the discovery of AP-3 demonstrated 
by EM that AP-3 coated vesicles were thinner than that of clathrin-coated vesicles and 
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Figure 1-6. AP-3 trafficking pathways. (A) Schematic representation of AP-3 complex. 
(B) AP-3 trafficking occurs from the trans-Golgi network (TGN) or early endosome (EE) 
to the multivesicular body (MVB) 
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did not co-localize with clathrin. In addition, the AP-3-coated vesicles did not copurify 
with clathrin (157, 158). Additional studies have demonstrated that inactivation or 
depletion of clathrin does not affect AP-3-dependent protein transport or AP-3 
association with membranes (169, 175). Immuno-colocalization studies of AP-3 and 
clathrin have produced mixed results (31, 131, 157). Nevertheless, the β3 subunit 
contains a clathrin-binding motif, LLDLD, known as the clathrin box, and has been 
shown to bind clathrin in vitro (31, 164). AP-3 has also been demonstrated to recruit 
clathrin onto synthetic liposomes (31, 41). However, protein sorting in AP-3 deficient 
cells has been shown to be partially rescued by a β3 mutant lacking the clathrin box, 
further providing evidence for clathrin-independent AP-3 function (131). These collective 
observations have made it difficult to assess the role of clathrin in AP-3 function.  
 
Regulation 
AP-3 recruitment to membranes is regulated by its interaction with the small 
GTP-binding protein, ADP-ribosylation factor 1 (ARF1). ARF1 can exist either in an 
active state or inactive state, and this active or inactive state is dictated by ARF1 binding 
to GTP or GDP, respectively. In the active GTP-bound state, ARF1 binds to membranes 
where it actively recruits coat components, such as AP-3 (123), which promotes vesicle 
budding. In the inactive GDP-bound state, ARF1 dissociates from membranes. ARF1 
membrane association or dissociation is dictated by its myristoylated N-terminal 
amphipathic helix, which acts as a molecular switch. When ARF1 is GDP-bound, the 
helix is folded into the protein, thus preventing membrane association. Conversely, when 
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ARF1 is GTP-bound, the myristoylated N-terminal helix becomes exposed and is 
anchored into the membrane (3). The factors that mediate ARF1 association with GTP or 
GDP are guanine nucleotide exchange factors (GEFs) and GTP-ase activating proteins 
(GAPs), respectively (39). GEFs exchange GDP for GTP, resulting in ARF1 activation. 
In contrast, GAPs promote ARF1 inactivation by inducing ARF1-mediated GTPase 
activity, resulting in the hydrolysis of GTP to GDP.  
As ARF1 functions at multiple sites and recruits as many as seven different 
vesicle coat proteins onto membranes, the specificity of recruitment for each coat 
component is thought to be mediated by ARF GAPs (112). The ARF GAP that regulates 
ARF1-mediated recruitment of AP-3 to membranes is the ubiquitously expressed ARF 
GAP with GTPase domain ankyrin repeat and PH domain 1 (AGAP1) (112, 114). 
AGAP1 is comprised of a GTP-binding protein-like domain (GLD); a split pleckstrin 
homology domain (PH), which mediates binding to the phospholipids; an ARF GAP 
domain; and ankyrin repeats, which mediate protein-protein interactions (95, 114, 179). 
The interaction between AGAP1 and AP-3 is mediated by the PH domain of AGAP1 and 
the AP-3 hemi-complex of δ and σ  (112). Overexpression of AGAP1 has been shown to 
disrupt AP-3 membrane association, which alters AP-3-mediated trafficking of LAMP-1, 
providing further evidence that AGAP1 plays a role in AP-3 function (112).    
 
3.4. Role of AP-3δ  in HIV-1 Replication 
A recent study suggested that AP-3 plays a critical role in HIV-1 assembly and 
intracellular Gag trafficking (40). The N-terminal helix of the MA domain of Gag was 
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shown to bind directly to the hinge domain of AP-3δ. When the MA:δ interaction was 
disrupted by depleting endogenous AP-3δ by RNA interference or overexpressing a 
truncated AP-3 dominant-negative mutant, HIV-1 production was severely compromised. 
Immunofluorescence studies revealed that disrupting the MA:AP-3δ interaction by 
overexpressing the dominant-negative AP-3 mutant resulted in the failure of Gag to 
localize with LEs/MVBs. Together, these results suggested that AP-3δ-mediated Gag 
trafficking to LEs/MVBs was required for subsequent Gag targeting to the plasma 
membrane in order for productive particle production to occur. In infected primary 
human dendritic cells, virus particles have been reported to accumulate in AP-3δ and 
CD81-enriched compartments and AP-3δ depletion results in a reduction in virus 
production and an increase in intracellular Gag levels (52), suggesting that AP-3δ plays a 
role in HIV-1 replication in this cell type in a non-MVB compartment. 
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CHAPTER II: MATERIALS AND METHODS 
 
2.1. Cell culture 
293T, HeLa, HeLa-LAV and TZM-bl cell lines  
293T and HeLa cell lines were obtained from the American Tissue Culture 
Collection. TZM-bl is a HeLa-derived cell line that expresses CD4, CCR5, and CXCR4 
and contains stably integraded copies of the β-galactosidase and luciferase genes, which 
are under the transcriptional control of the HIV-1 LTR. This cell line was obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH, from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. The HeLa-
LAV cell line is a HeLa derivative that expresses CD4 and CXCR4, is chronically 
infected with the HIV-1 BRU (LAV) strain, and expresses all viral proteins and produces 
infectious particles. This cell line was obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr. Joerg Berg and 
Dr. Matthias Wabl. Cells were grown in 100 mm tissue culture plates and maintained 
with Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% 
fetal bovine serum (FBS) (Invitrogen), 3.7 g/L sodium bicarbonate, 2.0 g/L HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 25000 units/L penicillin, and 25000 
ug/L streptomycin at 37°C, 5% CO2.   
Primary human monocyte-derived macrophages (MDM)  
Elutriated primary human monocytes were obtained through the University of 
Massachusetts Medical School CFAR Virology Core. Cells were seeded at a density of 
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1.25 X 106 cells per well in 6-well tissue culture plates and differentiated with Media A 
[DMEM (GIBCO) supplemented with 10% pooled human male AB serum (SeraCare), 2 
mM L-glutamine (Invitrogen), and 10 ng/mL macrophage colony stimulating factor 
(MCSF) (R&D Systems)] at 37°C, 5% CO2. Four days post cell seeding, and one day 
prior to transfection, cells were supplemented with 1 mL per well of macrophage media 
(Media A with no MCSF) and maintained at 37°C, 5% CO2.  
 
2.2. Virus Stock Preparation 
VSV-G/NL4-3Δenv and NL4-3(YU2) virus stocks were produced in 293T cells 
transfected with 10 µg pHEF-VSV-G and 10 µg of pNL4-3Δenv or 20 µg pNL4-3(YU2) 
using the calcium phosphate transfection method, respectively. One day prior to 
transfection, cells were seeded in 100 mm tissue culture plates with antibiotic-free media 
(10% FBS in DMEM), to yield a cell density of 70-75% confluence on the day of 
transfection. For each transfection reaction, 20 µg of the indicated DNA was combined 
with 124 mL 2 M calcium chloride and brought to a final volume of 1 mL with sterile 
water, followed by the drop-wise addition of 1 mL 2X HEPES Buffered Saline [50 mM 
HEPES pH 7.05, 10 mM KCl, 12 mM Glucose, 250 mM NaCl, 1.5 mM Na2HPO4] and 
subsequent incubation for 1-2 minutes at room temperature. For each plate, cell culture 
media was replaced with 8 mL fresh antibiotic-free media, with the addition of 5 µL of 
25 mM chloroquine. Transfection reactions were added to cells and cells were incubated 
at 37°C, 5% CO2. Approximately 14-16 hours post transfection, cell culture media was 
removed, cells were washed twice with 1X Phosphate Buffered Saline, pH 7.2 (PBS), 
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PBS was removed, and cells were re-fed with 6 mL of fresh antibiotic-free media. At 48 
hours post transfection, cell supernatants were collected and clarified by centrifugation at 
1200 rpm for 5 minutes at room temperature. Supernatants were aliquoted into cryovials 
and stored in liquid nitrogen.   
 
2.3. Virus Titration and Infectivity Assay 
Virus Titration 
TZM-bl cells were seeded at a density of 2.0 X 104 cells per well in a 48-well 
tissue culture plate with antibiotic-free media (10% FBS in DMEM) one day prior to 
infection. Virus was thawed at 37°C and diluted 1:10 in antibiotic-free media in a total 
volume of 300 mL, followed by four 300 uL 10-fold serial dilutions. Cell culture media 
was removed, and cells were infected in duplicate with 100 µL of undiluted virus, serially 
diluted virus, or antibiotic-free media alone (negative control). At 3 hours post-infection, 
0.5 mL of fresh antibiotic-free media was added to cells. At 48 days post-infection, cell 
culture supernatants were removed, cells were washed twice with 1X PBS and fixed with 
0.5% gluteraldehyde in 1X PBS for 15 minutes at 4°C. Cells were subsequently washed 
twice with 1X PBS and were stained immediately or stored at 4°C in 1X PBS. Following 
fixation, infected TZM-bl cells were stained with 200 µL staining solution [0.5 mg/mL 5-
bromo-4-chloro-indolyl-β-D-galactopyranoside (X-Gal) in 1X PBS containing 3 mM 
potassium ferrocyanide, 3 mM potassium ferricyanide, and 1 mM magnesium chloride] 
and incubated overnight at room temperature. Staining solution was removed and cells 
were washed twice with 1X PBS. Cells were visualized by light microscopy and infected, 
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blue cells were counted to determine the titer of the virus stock in infectious units (IU) 
per µL.  
Infectivity Assay 
For the infectivity assay, MDM-derived NL4-3(YU2) and HeLa-LAV-derived 
viruses were used to infect TZM-bl cells as described in the virus titration protocol, with 
undiluted virus and one 10-fold serial dilution. TZM-bl cells were infected with equal 
reverse-transcriptase activity units in a total volume of 300 uL. The assay was continued 
using the virus titration protocol.  
 
2.4. Cell Supernatant and Cell Harvesting 
Cell supernatants were removed from tissue culture wells and transferred to 1.5 
mL microfuge tubes. Due to the non-uniform evaporation of supernatants from well to 
well during incubation, the volume of each supernatant was measured and the supernatant 
volumes were normalized with antibiotic-free media for HeLa cell supernatants and 
macrophage media for MDM supernatants. Cell supernatants were clarified by 
centrifugation at 3000 rpm for 3 minutes at room temperature, followed by filtration 
through 0.45 µm PVDF filters. A portion (270 µL) of each supernatant was lysed with 30 
µL 0.5% Triton X-100 lysis buffer: 0.5% Triton X-100 in 0.25 M Tris, pH 7.4 and kept 
on ice. Another portion (900 uL) of each supernatant was transferred to 1.5 mL screw-cap 
microfuge tubes and centrifuged at 25000 x g for 2 hours at 4°C to pellet the virus 
particles, followed by removal of the supernatant. Cells were washed twice with 1X PBS, 
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scraped and collected into 1.5 mL microfuge tubes. Cells were pelleted by centrifugation 
at 14000 rpm for 1 minute at room temperature followed by removal of the supernatant.    
Uninfected cells were harvested using the same protocol. 
 
2.5. Reverse Transcriptase Activity Assay 
In a round-bottomed 96-well plate, 10 µL of lysed supernatants were added to 
wells containing 10 µL of solution A [100 mM Tris-HCl pH 7.9, 300 mM potassium 
chloride, 10 mM dithiothreitol, 0.1% Nonidet P-40 (Igepal CA-630) (Sigma Aldrich)] 
and incubated at 37°C for 15 minutes. Following incubation, 25 µL of solution B [50 mM 
Tris-HCl pH 7.9, 50 mM dithiothreitol, and 15 mM magnesium chloride] containing     
10 µCi [3H]-dTTP/mL, 10 µg/mL polyadenylic acid (poly rA), and 5 µg/mL oligo-dT18 
was added to wells, and the reactions were incubated overnight at 37°C. Supernatants 
were assayed in triplicate. The following day, reactions were pipetted onto circular 2.3 
cm DE81 ion exchange filters (Whatman) and air-dried. Filters were washed twice with 
2X SSC buffer [300 mM sodium chloride, 30 mM sodium citrate] for 5 minutes per wash 
at room temperature, and once with ethanol for 30 seconds at room temperature. Filters 
were air-dried and placed into scintillation vials, and 5 mL scintillation fluid (EcoScint H, 
National Diagnostics) was added to each vial. Samples were analyzed in a liquid 
scintillation counter programmed to detect tritium for 1 minute per scintillation vial.  
 
2.6. β-galactosidase activity assay 
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 Infected TZM-bl cell lysates (15 µg total protein) were incubated with 1.5 µL 100 
mM MgCl2, 33 µL ONPG (ortho-nitrophenyl-β-D-galactopyranoside) (Sigma), 100.5 µL 
0.1 M Na2HPO4/NaH2PO4, pH 7.5, for 1 hour at 37°C. After incubation, 100 µL of each 
reaction was added to 900 µL dH2O and spectrophotometrically analyzed at an 
absorbance of 420 nm.  
 
2.7. SDS-PAGE and Western blot analysis of viral and cellular lysates  
Cell pellets were lysed with 0.5% Triton X-100 lysis buffer on ice for 30 minutes 
and clarified by centrifugation at 14000 rpm for 10 minutes at 4°C, followed by transfer 
of clarified cell lysates to new tubes. Total protein concentration in the cell lysates was 
determined by Bradford protein assay. A total protein amount of 10 or 15 µg for each cell 
lysate was aliquoted into new tubes with 5X SDS loading buffer [62.5 mM Tris-HCL pH 
6.8, 10% glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, 0.0625% 
bromophenol blue], volumes were normalized with water, and samples were boiled for 4 
minutes. Pelleted virus particles were lysed with 10 µL 0.5% Triton X-100 lysis buffer on 
ice. A volume of 2.5 mL of 5X SDS loading buffer was added to each lysate and samples 
were boiled for 4 minutes. Cellular and viral lysates were analyzed by 6%, 8%, 10%, or 
12% SDS-PAGE, for the downstream detection of AP-3δ, HA-AGAP1 and HA-
AGAP1[R599K], cell-associated Gag, or virus-associated Gag, respectively. Gels were 
electrophoresed with Tris-Glycine-SDS-PAGE Buffer [25 mM Tris, 192 mM glycine, 
0.1% SDS] (National Diagnostics) followed by transfer onto Immobilon-P PVDF 
membranes with transfer buffer [10% methanol in Tris-Glycine-SDS-PAGE Buffer] for 
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50-55 minutes at 100 mA, using the semi-dry transfer method. Membranes were blocked 
in blocking solution: 10% dry milk in 1X TBS-T [0.1M Tris pH 7.4, 0.1M Tris pH 8.0, 
0.5% Tween-20] for at least 1 hour at room temperature with gentle agitation. Blots were 
incubated overnight at 4°C in primary antibody, with gentle agitation. The following day, 
blots were washed 3 times with 1X TBS-T for 5 minutes per wash. Blots were incubated 
for 1 hour at room temperature in horseradish peroxidase (HRP)-conjugated secondary 
antibody diluted in 2 mL of blocking solution, with gentle agitation. Blots were washed 3 
times with 1X TBS-T for 5 minutes per wash, incubated for 1 minute in ECL reagent (GE 
Healthcare Life Sciences), followed by exposure to Hyperfilm (GE Healthcare Life 
Sciences). The following antibodies were used: mouse monoclonal anti-adaptin δ (BD 
Transduction Laboratories), mouse monoclonal anti-p24 (NIH AIDS Research and 
Reference Reagent Program), mouse monoclonal anti-HA.11 (Covance), goat polyclonal 
anti-hRIP (Santa Cruz Biotechnology), rabbit polyclonal anti-CRM1 (Santa Cruz 
Biotechnology), and rabbit polyclonal anti-Sam68 (Santa Cruz Biotechnology).  
 
2.8. siRNA Transfection 
HeLa, HeLa-LAV, and TZM-bl cell lines 
One day prior to transfection, cells were seeded at a density of 1.25 X 105 
cells/well in 6-well plates with antibiotic-free media (10% FBS in DMEM) to achieve a 
cell density of 40-50% confluence on the day of transfection. Cells were transfected using 
Oligofectamine (Invitrogen) transfection reagent per the manufacturer’s protocol for 
transfection in a 6-well tissue culture plate format. For each transfection reaction, 4 uL of 
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Oligofectamine was diluted in 11 uL OPTIMEM-I (Invitrogen) reduced serum media and 
incubated for 10 minutes at room temperature. siRNA was diluted in a final volume of 
185 µL with OPTIMEM-I and combined with the 15 µL oligofectamine/OPTIMEM-I 
mixture, followed by incubation at room temperature for 20 minutes. Cell culture media 
was removed, cells were washed once with DMEM, DMEM was removed, and the cells 
were fed with 0.8 mL/well of fresh DMEM. Transfection reactions were added to cells, 
followed by incubation at 37°C, 5% CO2. Four hours post transfection, 0.5 mL of 30% 
FBS in DMEM was added to each well. Cells were maintained at 37°C, 5% CO2 for the 
duration of the transfection.  
MDM 
Cells were cultured and differentiated as described in 2.1. siRNA transfection was 
performed using Lipofectamine 2000 (Invitrogen). For each transfection, 5 µL 
Lipofectamine 2000 was diluted in 495 µL OPTIMEM-I and incubated at room 
temperature for 5 minutes. siRNA was diluted in a final volume of 500 µL with 
OPTIMEM-I and combined with the Lipofectamine 2000/OPTIMEM-I mixture, followed 
by incubation at room temperature for 20 minutes. Conditioned cell culture media was 
removed from cells and mixed with fresh macrophage media at a 1:1 ratio to generate 
50/50 macrophage media. Prior to the addition of the transfection reactions, cells were 
washed twice with 1X PBS, followed by PBS removal with a serological pipette, due to 
cell sensitivity to aspiration. Transfection reactions were added to cells, followed by 
incubation at 37°C, 5% CO2. Four hours post transfection, transfection reactions were 
removed and cells were washed twice with 1X PBS. PBS was removed and 1.5 mL per 
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well of 50/50 macrophage media was added to the cells. Cells were maintained at 37°C, 
5% CO2 for the duration of the transfection.  
 
2.9. siRNA duplexes 
Nonsilencing siRNA 
The proprietary AllStars Negative Control siRNA (siANC) was obtained from Qiagen 
and has no known homology to any mammalian gene.     
AP-3δ-specific siRNA 
AP-3δ 1-4 siRNAs [siAP-3δ(1)-(4)] and siAP-3δ5 were previously published in (40) and 
(20), respectively.  These twenty-one nucleotide siRNA duplexes with 3’dTdT overhangs 
were manufactured by Qiagen. The target region of AP-3δ, sense, and anti-sense 
sequences in the direction of 5’ to 3’ are included for each AP-3δ siRNA.  
siAP-3δ(1) target region: nt 176-194  
sense: UCUGCAAGCUGACGUAUUUTT; anti-sense: AAAUACGUCAGCUUGCAGATT 
siAP-3δ(2) target region: nt 489-507 
sense: GAAGAAGGCUGUGCUGAUCTT; anti-sense: AAAUACGUCAGCUUGCAGATT  
siAP-3δ(3) target region: nt 2438-2456 
sense: GCGAGAAACUGCCUAUUCATT; anti-sense: UGAAUAGGCAGUUUCUCGCTT 
siAP-3δ(4) target region: nt 2493-2511  
sense: GAAGGACGUUCCCAUGGUATT; anti-sense: UACCAUGGGAACGUCCUUCTT 
siAP-3δ(5) target region: nt 3159−3177  
sense: CCCUGUCCUUCAUUGCCAATT; anti-sense: TTGGCAATGAAGGACAGGGTT  
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hRIP-specific siRNA 
This twenty-one nucleotide siRNA duplex with 3’dTdT overhangs was published in 
(151), and manufactured by Qiagen. The target region of hRIP, sense, and anti-sense 
sequences in the direction of 5’ to 3’ are included. 
sihRIP target sequence: nt 647-665 
sense: GCCAAAGUCGUGGCAUCAGTT; anti-sense: CUGAUGCCACGACUUUGGCTT 
 
2.10. DNA Transfection 
One day prior to transfection, cells were seeded at a density of 1.5 X 105 
cells/well in 6-well plates with antibiotic-free media (10% FBS in DMEM) to achieve a 
cell density of 60-70% confluence on the day of transfection. Cells were transfected using 
FugeneHD (Roche) transfection reagent per the manufacturer’s protocol for transfection 
in a 6-well tissue culture plate format. For each transfection, 2 µg of DNA was diluted in 
100 mL of OPTIMEM-I followed by the addition of 3 mL of FugeneHD. Reactions were 
incubated at room temperature for 15 minutes, followed by the addition of the reactions 
to the cells. Cells were kept at 37°C, 5% CO2 for the duration of the experiment. For 
virus experiments, cells were transfected with 0.5 µg pHA-AGAP1stop, pHA-AGAP1, or 
pHA-AGAP1[R599K] + 1.5 µg pUC118, or 1.0 µg pHA-AGAP1stop, pHA-AGAP1, or 
pHA-AGAP1[R599K] + 1.0 µg pUC118. For immunofluorescence experiments, cells 
were transfected with 2 µg of pHA-AGAP1stop, pHA-AGAP1, or pHA-
AGAP1[R599K]. For co-transfection experiments, cells were transfected with 2 µg of 
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pHA-AGAP1stop, pHA-AGAP1, or pHA-AGAP1[R599K] using the FugeneHD 
transfection method. At 24 hours post-transfection, cells were trypsinized and reseeded 
onto glass coverslips, followed by transfection with Attractene (Qiagen) transfection 
reagent, per the manufacturer’s protocol for transfection in a 6-well tissue culture plate 
format. For each transfection, 1.2 µg pCO-Gag-GFP or pCO-GagK29E/K31E-GFP was 
diluted in DMEM followed by the addition of 4.5 µL Attractene (Qiagen) per 
transfection. The reactions were incubated for 15 minutes at room temperature and were 
added to the cells. Cells were incubated at 37°C, 5% CO2 for the duration of the 
experiment.  
 
2.11. Plasmids 
pHEF-VSV-G: the expression vector for the glycoprotein of vesicular stomatitis virus  
(VSV-G), was obtained through the AIDS Research and Reference Reagent  
Program, Division of AIDS, NIAID, NIH: pHEF-VSVG from Dr. Lung-Ji Chang 
pNL4-3: the chimeric proviral clone encoding a the NY5 and LAV HIV strains, was  
obtained through the AIDS Research and Reference Reagent Program, Division  
of AIDS, NIAID, NIH: pNL4-3 from Dr. Malcolm Martin 
pNL4-3Δenv: a pNL4-3 derivative that contains two tandem premature stop codons in  
env, as a result of a single nucleotide insertion in the Nde I site of env. pNL4-
3Δenv was generated using the QuikChange site-directed mutagenesis kit 
(Stratagene), pNL4-3 as the template, and the following oligos:  
forward: 5’CAGATGCTAAAGCATAATGATACAGAGGTAC 3’ 
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reverse:  5’GTACCTCTGTATCATTATGCTTTAGCATCTG 3’ 
pNL4-3(YU2): a pNL4-3 derivative that encodes the env gene of the YU2 strain in place  
of NL4-3 env. (received from Dr. Joseph Sodroski) 
pEGFP-CO-Gag: an expression vector that generates codon-optimized NL4-3 Gag with  
an N-terminal EGFP tag. (received from Dr. Heinrich Gottlinger) 
pEGFP-CO-GagK29E/K31E: a pEGFP-CO-Gag derivative that contains two K to E  
amino acid substitutions at positions 29 and 31 (numbering based on G at position 
1, after M is removed during N-terminal myristylation), which have been shown 
to target Gag to MVBs (120). This expression vector generates codon-optimized 
NL4-3 GagK29E/K31E with an N-terminal EGFP tag. This construct was 
generated using the QuikChange site-directed mutagenesis kit (Stratagene), 
pEGFP-CO-Gag as the template, and the following oligos: 
forward: 5’GGCAAGAAGCAGTACGAGCTGGAGCACATCGTGTGGGCC 3’ 
reverse:  5’GGCCCACACGATGTGCTCCAGCTCGTACTGCTTCTTGCC 3’ 
pHA-AGAP1: an expression vector that generates wild-type AGAP1 with an N-terminal  
HA tag. AGAP1 was cloned by PCR into the Xho I and Not I sites of pCMV-HA 
(Clontech) using pCI-FLAG-AGAP1 (received from Dr. Paul Randazzo) as the 
template and the following oligos:    
forward: 5’CCCGGGGAATTCGGAACTACCAGCAGCAGCTGGCCAACTCGGCT3’   
reverse:  5’CCCGGGGCGGCCGCTCAGATGATGGTGGGCACCCTCCCACTGCT3’ 
pHA-AGAP1[R599K]: an expression vector that generates mutant AGAP1 with an N- 
terminal HA tag that lacks GAP activity as a result of an R to K amino acid  
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substitution at position 599. AGAP1[R599K] was cloned by PCR into the Xho I 
and Not I sites of pCMV-HA (Clontech) using pCI-FLAG-[R599K]AGAP1 
(received from Dr. Paul Randazzo) as the template and the following oligos:    
forward: 5’CCCGGGGAATTCGGAACTACCAGCAGCAGCTGGCCAACTCGGCT3’   
reverse:  5’CCCGGGGCGGCCGCTCAGATGATGGTGGGCACCCTCCCACTGCT3’ 
pHA-AGAP1[stop]: is a pHA-AGAP1 derivative that encodes but does not  
express AGAP1 due to the introduction of two premature stop codons in the HA  
coding region. This construct was generated using the QuikChange II site-directed  
mutagenesis kit (Stratagene) using pHA-AGAP1 as the template and the  
following oligos: 
forward: 5’CCCACCATGTACCCATAGTGATGTTCCAGATTACGC 3’ 
    
reverse:  5’GCGTAATCTGGAACATCACTATGGGTACATGGTGGG 3’   
pUC118: cloning vector obtained from the ATCC 
 
2.11. Indirect Immunofluorescence  
Cells seeded on glass coverslips were washed twice with 1X PBS, followed by 
fixation in ice cold methanol for 5 minutes at -20°C. Cells were washed once with 1X 
PBS for 5 minutes at room temperature and stored in 70% ethanol overnight. On the day 
of staining, cells were washed 3 times with 1X PBS for 5 minutes per wash and incubated 
in blocking solution  (1% (w/v) bovine serum album (BSA) in 1X PBS) for 1 hour at 
room temperature. Cells were incubated overnight with gentle agitation in primary 
antibody diluted in blocking solution at 4°C. The following day, cells were washed 3 
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times in 0.1% BSA in 1X PBS for 5 minutes per wash, followed by incubation with 
Alexa Fluor 488- and/or Alexa Fluor 594-conjugated secondary antibodies diluted in 1.5 
mL of 1% BSA in 1X PBS for 1 hour at room temperature protected from light. Cells 
were washed three times with 1X PBS for 5 minutes per wash, with the addition of DAPI 
diluted 1:10000 (from a 1 µg/µL stock) during the second 1X PBS wash. Following the 
third 1X PBS wash, cells were washed with water for 5-10 minutes. Cells were mounted 
onto glass slides, with ProLong Gold Antifade mounting medium (Invitrogen). Slides 
were dried overnight at room temperature. Cells were viewed with a Zeiss Axioplan 2 
wide-field epifluorescence microscope equipped with a 63X Plan Apochromat objective. 
Images were acquired and analyzed using OpenLab 2.2.5. software. For the detection of 
endogenous AP-3δ, HA, and CD63 in HeLa cells, goat polyclonal anti-AP-3δ primary 
antibody (Santa Cruz Biotechnology, SCB) with AlexaFluor (AF) 488 or 594-conjugated 
donkey anti-goat secondary antibody; rabbit polyclonal anti-HA primary antibody (Santa 
Cruz Biotechnology) with AF594-conjugated chicken anti-rabbit secondary antibody; and 
mouse-monoclonal anti-CD63 primary antibody (SCB) with AF594-conjugated goat anti-
mouse secondary antibody were used, respectively. For the detection of AP-3δ, HIV-1 
Gag, and CD63 in HeLa-LAV cells, mouse monoclonal anti-AP-3δ primary antibody 
(BD Transduction Laboratories) with AF546-conjugated goat anti-mouse secondary 
antibody; rabbit polyclonal anti-p24 primary antibody (Advanced Biotechnologies) with 
AF488-conjugated goat anti-rabbit; and mouse-monoclonal anti-CD63 primary antibody 
(SCB) with AF546-conjugated goat anti-mouse secondary antibody was used. All AF-
conjugated secondary antibodies were from Invitrogen.  
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CHAPTER III: THE ROLE OF AP-3 IN HIV-1 PRODUCTION 
 
3.1. Introduction 
The highly coordinated process of HIV-1 particle production is directed by the 
viral structural protein Gag that is both necessary and sufficient for particle production as 
evidenced by its ability to form virus-like particles in the absence of other viral 
components (55, 155). Particle production involves a series of steps that include Gag 
targeting to membranes that serve as viral assembly sites, Gag binding to membranes, 
Gag-multimerization, and Gag-mediated viral budding and release (170). Gag mediates 
each of these steps through the functions of its distinct domains: MA, CA, NC, and p6 
(47, 57). The MA domain targets and binds Gag to membranes, the CA and NC domains 
facilitate Gag multimerization (119), and the p6 domain mediates viral budding and 
release through its recruitment and interaction with the endosome sorting complex 
required for transport (ESCRT) machinery (161, 162). Although significant progress has 
been made in understanding the role of Gag in the steps of particle production, the 
mechanism by which Gag is targeted to sites of virus assembly is unknown.  
Gag is targeted to two sites of virus assembly in T-cells, macrophages, and cell 
lines (ie. HeLa and 293T): the plasma membrane (PM) (43, 59, 81, 118, 121, 173) and 
multivesicular bodies (MVBs) (59, 61, 115, 120, 126, 132, 134, 144, 154). However, in 
T-cells and experimental cell lines, the plasma membrane (PM) is the predominant site of 
virus assembly whereas the MVB serves as the predominant site of virus assembly in 
macrophages (120). Ultimately, Gag must be targeted to the PM as assembled virus 
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particles must traverse the PM to exit the cell. Furthermore, abolishment of Gag targeting 
to the PM has been demonstrated to significantly inhibit virus production (118). The 
necessity for Gag targeting to and subsequent virus assembly in MVBs is less clear, 
despite evidence to support a productive role for virus assembly in these compartments. 
Studies have demonstrated that viruses derived from the MVBs of chronically infected T-
cells, macrophages, and HIV-1 expressing 293T cells are infectious (61, 132). In 
addition, treatment of chronically infected T-cells and HIV-1-expressing 293T cells with 
ionomycin, a trigger of MVB-mediated exocytosis, stimulates virus release (61). 
Exocytosis of MVB-containing virus particles has also been observed in infected 
macrophages (110, 132), suggesting that exocytosis may be the principle mechanism of 
particle release for virions that assemble into MVBs. In addition, live imaging of newly 
synthesized Gag demonstrated that Gag traffics along an intracellular route that begins at 
the perinucleus, proceeds to MVBs, and ends at the PM, suggesting that Gag trafficking 
to MVBs occurs prior to its localization at the PM (134). Furthermore, the ESCRT 
machinery is typically associated with MVBs as a result of its function in MVB 
biogenesis (reviewed in (62)). Therefore, Gag may be targeted to MVBs to recruit the 
ESCRT machinery required for virus budding and release. Taken together, these results 
raise the possibility that MVBs are productive sites for virus assembly and suggest that 
Gag trafficking to MVBs serves as an intermediate step in subsequent localization to the 
PM. However, the specific mechanism by which Gag traffics to MVBs remains unclear.  
One possible mechanism of Gag trafficking to MVBs was revealed in a study of 
Adaptor Protein Complex 3 (AP-3), a cellular binding partner for Gag that was 
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implicated in mediating Gag trafficking to MVBs (40). AP-3 is a heterotetrameric protein 
complex that mediates vesicular transport of lysosomal membrane proteins to MVBs (6, 
147). AP-3 is comprised of two large subunits: β and δ, one medium subunit, µ, and one 
small subunit, σ (32, 158). The N-terminal H1 helix of the MA domain of Gag was 
demonstrated to specifically bind the δ subunit of AP-3 (AP-3δ), and disruption of the 
AP-3δ:MA interaction was reported to inhibit Gag trafficking to MVBs and negatively 
effect virus production (40). These results suggest that Gag trafficking to MVBs is 
necessary for productive for viral replication and is dependent on AP-3δ for this process. 
However, it is unknown whether AP-3δ plays a similar role in infected primary 
macrophages, which are natural targets of HIV and promote virus assembly primarily at 
MVBs. In addition, the role of AP-3δ function in virally infected cells that promote virus 
assembly primarily at the plasma membrane remains to be determined.  
Here, we investigate the role of AP-3δ in HIV-1 production in infected HeLa 
cells, chronically infected HeLa-LAV cells, and primary human monocyte-derived 
macrophages (MDMs). We also investigate the role of the regulator of AP-3 function, 
AGAP1, in HIV-1 production in infected HeLa cells. Our results demonstrate that RNAi-
mediated depletion of endogenous AP-3δ does not effect HIV-1 production in infected 
HeLa, HeLa-LAV, and primary human MDMs nor does it affect viral infectivity or cell 
permissiveness to viral infection. Curiously, through an individual test of a panel of AP-
3δ-specific siRNAs we observed inhibition of virus production with two of the five 
siRNAs tested. These siRNAs share the same sequences with siRNAs that have been 
used in two studies that demonstrated severe inhibition on virus production in cells 
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treated with these siRNAs. Finally, we demonstrated that specific regulation of AP-3 by 
AGAP1 does not alter HIV-1 production, further suggesting that AP-3 is not required for 
HIV-1 production. 
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3.2. Results 
3.2.1. Depletion of endogenous AP-3δ has no discernible effect on HIV-1 production 
Previous studies have demonstrated that AP-3δ plays a significant role in HIV-1 
production in transfected HeLa cells (20, 40), however, the role of AP-3δ in the 
production of virus particles in infected cells is unknown. In order to investigate the role 
of AP-3δ in the more biologically relevant context of host cell infection, HeLa cells were 
treated with transfection reagent alone [mock], a non-silencing control siRNA (siANC), 
and an AP-3δ-specific siRNA (siAP-3δ(1)), for 48 hours when near complete depletion 
of AP-3δ was observed (Fig. A2-1). Cells were subsequently infected with VSV-G-
pseudotyped HIV-1 NL4-3Δenv (VSV-G/NL4-3Δenv) virus for 48 hours followed by 
harvesting of the cell supernatants and cells. The cell supernatants were assayed for the 
presence of virus particles, using a standard enzymatic reverse-transcriptase (RT) activity 
assay (90), and cell and viral lysates were assayed for protein expression by SDS-PAGE 
and Western blot. Nearly undetectable  levels of AP-3δ were observed HeLa cells treated 
with siAP-3δ(1) whereas basal levels of AP-3δ were observed in the mock and siANC-
treated cells (Fig. 3-1B). Depletion of AP-3δ did not affect the level of intracellular Gag 
expression nor did it affect extracellular p24 expression (Fig. 3-1B). Supernatants from 
siAP-3δ(1)-treated cells retained full RT activity when compared to both mock and 
siANC-treated cells (Fig. 3-1A). As a positive control for virus inhibition, cells were 
treated with hRIP-specific siRNA to demonstrate that the experimental conditions would 
allow for the detection of inhibited virus production (Fig. A2-2A). Collectively, these  
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Figure 3-1. Effect of AP-3δ  depletion on HIV-1 production in infected HeLa cells. 
HeLa cells were transfected with reagent alone (Mock), 50 nM non-silencing siRNA 
[siANC], and 50 nM AP-3δ specific siRNA (siAP-3δ(1)). At 48 hours post transfection, 
cells were infected with VSV-G/NL4-3Δenv (MOI = 0.25). At 48 hours post infection, 
cell supernatants and cells were harvested. (A) Cell supernatants were analyzed for HIV-
1 production using a standard enzymatic reverse transcriptase (RT) activity assay. Bars 
represent the mean percentages of mock ± SEM for three independent experiments 
performed in duplicate. The RT activities (counts per minute/10µL of supernatant) of the 
cell supernatants derived from mock-treated cells were: 48653.94, 54598.62, and 
62509.72. (B) Cell and viral lysates were analyzed by SDS-PAGE and Western blot with 
anti-AP-3δ, anti-p24, and anti-Sam68 antibodies. 
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results demonstrate that AP-3δ is not required for virus production in HeLa cells. 
To further evaluate the role of AP-3δ in virus production we next examined 
whether AP-3δ depletion had an effect on HIV-1 production in cells chronically infected 
with HIV-1 BRU (LAV) that expresses CD4, CCR5, and CXCR4, and supports the 
production of wild-type infectious virus particles at high levels (9). HeLa-LAV cells were 
transfected with transfection reagent alone (mock), siANC, or siAP-3δ(1) for 72 hours, 
followed by supernatant removal and re-feeding of the cells. At 12 hours post-feeding, 
cell supernatants and cells were harvested. Similar to the HeLa cells, siAP-3δ(1) 
treatment efficiently and specifically depleted AP-3δ in HeLa-LAV cells and additionally 
had no effect on intracellular Gag expression (Fig. 3-2B). No discernible difference in 
supernatant RT activity (Fig. 3-2A) and p24 expression in viral lysates (Fig. 3-2B) 
between mock, siANC, and siAP-3δ-treated cells was observed. These results 
demonstrate that AP-3δ is also not required for virus production in chronically infected 
HeLa-LAV cells.  
 We next investigated whether AP-3δ depletion had an effect on virus production 
in a natural target of HIV-1 infection, namely, primary human monocyte-derived 
macrophages (MDM). In addition to their role as natural targets of HIV-1 infection, 
MDMs promote virus particle production in multivesicular bodies. Monocytes obtained 
from donor blood were differentiated into MDM for five days and were treated with 
transfection reagent alone (mock), siANC, and siAP-3δ(1). At 48 hours post-transfection, 
the MDMs were infected by spinoculation with HIV-1 NL4-3(YU2), a chimeric  
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Figure 3-2. Effect of AP-3δ  depletion on HIV-1 production in chronically infected 
HeLa-LAV cells. HeLa-LAV cells were transfected with reagent alone (Mock), 100 nM 
siANC, and 100 nM siAP-3δ. At 72 hours post transfection, cell culture media was 
changed. At 12 hours post-media change, cell supernatants and cells were harvested. (C) 
Cell culture supernatants were analyzed for HIV-1 production by RT activity assay. Bars 
represent the mean percentages of mock ± SEM for three independent experiments. The 
RT activities (counts per minute/10µL of supernatant) of the cell supernatants derived 
from mock-treated cells were: 22869.78, 24675.79, and 36179.89. (D) Cell and viral 
lysates were analyzed by SDS-PAGE and Western blot with anti-AP-3δ, anti-p24, and 
anti-Sam68 antibodies. 
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Figure 3-3. Effect of AP-3δ  depletion on HIV-1 production in primary human 
monocyte-derived macrophages (MDM). Primary human monocyte-derived 
macrophages (MDMs) differentiated for five days followed by transfection with reagent 
alone (Mock), 10 nM siANC, and 10 nM siAP-3δ. At 48 hours post transfection, cells 
were infected with NL4-3(YU2) (MOI = 1.0). At five days post infection, cell 
supernatants and cells were harvested. (E) Cell culture supernatants were analyzed for 
HIV-1 production by RT activity assay. Bars represent the mean percentages of Mock ± 
SEM for three independent experiments performed in duplicate. The RT activities (counts 
per minute/10µL of supernatant) of the cell supernatants derived from mock-treated cells 
were: 7341.34, 25015.44, and 37211.05. (F) Cell and viral lysates were analyzed by SDS-
PAGE and Western blot with anti-AP-3δ, anti-p24, and anti-CRM1 antibodies.  
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virus that expresses the envelope of the macrophage-tropic YU2 strain in an NL4-3 
background. At 24 hours post-infection, cell supernatants were removed and cells were  
washed and re-fed with fresh media. At five days post-infection, cell supernatants and 
cells were harvested and analyzed for virus production and protein expression. Efficient 
and specific depletion of AP-3δ was observed in the siAP-3δ(1)-treated MDM lysates, 
whereas intracellular Gag expression was unaffected (Fig. 3-3B). No discernible 
difference in RT activity (Fig. 3-3A) and p24 expression in viral lysates (Fig. 3-3B) 
between mock, siANC, and siAP-3δ-treated cells was detected. As a positive control for 
virus inhibition, cells were treated with hRIP-specific siRNA to demonstrate significant 
inhibition of virus production under similar experimental conditions (Fig. A2-2B). These 
results indicate that AP-3δ is not required for virus production in primary human MDMs. 
 
3.2.2. Virus particles produced from AP-3δ depleted cells are infectious 
 Although our results suggest that virus production is unaffected by the depletion 
of AP-3δ in infected cells, it is unclear whether the particles produced are infectious. In 
order to determine the infectivity of the viral particles, TZM-bl indicator cells were 
incubated with the cell supernatants from infected AP-3δ-depleted cells and then assayed 
for productive infection. TZM-bl is a HeLa-derived cell line that stably expresses high 
levels of CD4, CCR5, and CXCR4 and has been engineered to stably express the β-
galactosidase (β-gal) and firefly luciferase genes under the transcriptional control of the  
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Figure 3-4. Effect of AP-3δ  depletion on HIV-1 infectivity. TZM-bl cells were 
infected with virus derived from Mock, siANC, or siAP-3δ-treated HeLa-LAV cells or 
NL4-3(YU2)-infected MDMs. At 48 hours post infection, cells were fixed and stained. 
(A) Bars represent the viral titer as mean of percentages of Mock ± SEM for three 
experiments, assayed in duplicate. Viral titers (in infectious units/µL) for mock-treated 
HeLa-LAV cell supernatants were: 4.40, 8.00, and 11.35. (B) Bars represent the viral titer 
as mean of percentages of mock ± SEM for two independent experiments assayed in 
duplicate. Viral titers (in infectious units/µL) for mock-treated MDM cell supernatants 
were: 48.00 and 65.50.  
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HIV-1 long terminal repeat (LTR) (171). Productive infection of TZM-bl cells induces 
the expression of β-gal and luciferase, which can be readily detected by direct 
quantification methods. Cells were separately infected with equivalent RT units of virus 
derived from mock, siANC, and siAP-3δ(1)-transfected HeLa-LAV and NL4-3(YU2)-
infected MDM cells. At 48 hours post-infection, cells were fixed and treated with X-gal, 
a β-gal substrate that results in the blue staining of cells that express β-gal, an indicator of 
productive infection. Direct quantification of the infected cells demonstrated comparable 
levels of infection by the cell supernatants derived from mock, siANC, and siAP-3δ-
transfected HeLa-LAV (Fig. 3-4A) and MDMs (Fig. 3-4B), suggesting that virus 
particles produced from AP-3δ-depleted cells retain wild-type infectivity.  
 
3.2.3. AP-3δ-depleted cells are permissive to HIV-1 infection 
 We next investigated the role of AP-3δ-depletion on cell permissiveness to HIV-1 
infection. TZM-bl cells were treated with reagent alone (mock), siANC, or siAP-3δ(1) 
and infected with VSV-G/NL4-3Δenv for 48 hours. The permissiveness of cells to 
infection was assayed by measuring the levels of β-gal activity in the cell lysates. 
Efficient and specific AP-3δ depletion was observed in siAP-3δ(1)-treated cell lysates 
whereas intracellular Gag expression was unaffected (Fig. 3-5B). In addition, the levels 
of β-gal activity were comparable across the mock, siANC, and siAP-3δ(1)-treated cell 
lysates (3-5A), demonstrating that cell permissiveness to HIV-1 infection is not affected 
by AP-3δ depletion.  
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Figure 3-5. Effect of AP-3δ  depletion on permissiveness to HIV-1 infection. TZM-bl 
cells were transfected with reagent alone (Mock), siANC (50 nM), and siAP-3δ (50 nM). 
At 48 hours post-transfection, cells were infected with VSV-G/NL4-3Δenv (MOI = 0.25). 
At 48 hours post-infection, cell supernatants and cells were harvested. (A) Cell lysates 
were assayed for β-galactosidase activity. Bars represent β-galactosidase activity as mean 
percentages of Mock ± SEM for a duplicate experiment, assayed in duplicate. (B) Cell 
lysates were analyzed by Western blotting with anti-AP-3δ, anti-p24, and anti-Sam68 
antibodies.   
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3.2.4. Evaluation of the effects of siRNA-mediated AP-3δ depletion on HIV-1 production 
using a panel of AP-3δ-specific siRNAs  
 To address the discrepancy regarding the effect of AP-3δ depletion on HIV-1 
production between our results and previously published results (20, 40), we 
systematically examined a panel of five individual AP-3δ-specific siRNAs that share the 
target sequences with those previously studied. The silencing efficiency of each AP-3δ-
specific siRNA was first investigated by transfection of HeLa cells with siANC or each 
of the five siRNAs, siAP-3δ(1)-(5). AP-3δ depletion was observed in all siAP-3δ(1)-(5)-
treated cells with similar efficiencies (Fig. A2-3). We next tested the effect of siAP-
3δ(1)-(5)-mediated AP-3δ depletion on HIV-1 production in chronically infected HeLa-
LAV cells and infected HeLa and MDM cells. HeLa-LAV and MDM cells were treated 
with siANC or individually with siAP-3δ(1)-(5). HeLa-derived cell supernatants treated 
with siANC siAP-3δ(1), and siAP-3δ(4) exhibited full levels of comparable RT activity 
(Fig. 3-6A) whereas those treated with siAP-3δ(2), siAP-3δ(3), and siAP-3δ(5) exhibited 
~63%, 52%, and 88% reduction in RT activity, respectively, when compared to siANC-
treated cell supernatants (Fig. 3-6A). The observed level of AP-3δ depletion was similar 
for siAP-3δ(1)-(4), however siAP-3δ(5)-mediated AP-3δ depletion was slightly less 
efficient (Fig. 3-6B). In addition, the levels of intracellular Gag expression in siAP-3δ(2), 
siAP-3δ(3), and siAP-3δ(5)-treated HeLa lysates were reduced in comparison to that of 
siAP-3δ(1) and siAP-3δ(4)-treated cells (Fig. 3-6B). In HeLa-LAV cells, AP-3δ was 
efficiently depleted with siAP-3δ(1)-(5) to similar degrees  
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Figure 3-6. Effect of AP-3δ  depletion on HIV-1 production using a panel of AP-3δ-
specific siRNAs. HeLa cells were transfected with 50 nM of siANC or each of siAP-
3δ(1)-(5) followed by infection with VSV-G/NL4-3Δenv (MOI = 0.25). At 48 hours post-
transfection, cell supernatants and cells were harvested. (A) Cell supernatants were 
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analyzed for virus production by RT activity assay. Bars represent mean RT activity as 
mean percentages of siANC ± SEM for a single experiment, performed in duplicate. The 
RT activity (counts per minute/10µL of supernatant) of the cell supernatant derived from 
siANC-treated cells was 7958.85. (B) Cell lysates were analyzed for protein expression 
by SDS-PAGE and Western blot with anti-AP-3δ, anti-p24, and anti-Sam68 antibodies. 
HeLa-LAV cells were transfected with 100 nM of siANC or each of siAP-3δ(1)-(5) for 
72 hours, followed by media change. At 12 hours post-media change, cell supernatants 
and cells were harvested. (C) Cell supernatants were assayed for virus production by RT 
activity assay. Bars represent mean RT activity as mean percentages of siANC ± SEM for 
three independent experiments. The RT activities (counts per minute/10µL of 
supernatant) of the cell supernatants derived from siANC-treated cells were: 23172.36, 
31170.03, and 32625.70. (D) Cell lysates were analyzed for protein expression by SDS-
PAGE and Western blot with anti-AP-3δ, anti-p24, and anti-Sam68 antibodies. MDM 
cells were differentiated for five days, followed by transfection with 10 nM of siANC or 
each of siAP-3δ(1)-(5) for 48 hours. Cells were infected with NL4-3(YU2) (MOI = 1.0) 
and cell supernatants and cells were harvested five days post-infection. (E) Cell 
supernatants were assayed for virus production by RT activity assay. Bars represent RT 
activity as mean percentages of siANC ± SEM for three independent experiments 
performed in duplicate. The RT activities (counts per minute/10µL of supernatant) of the 
cell supernatants derived from siANC-treated cells were: 16594.69, 20322.83, and 
26710.42. (F) Cell lysates were analyzed for protein expression by SDS-PAGE and 
Western blot with anti-AP-3δ, anti-p24, and anti-CRM1 antibodies.   
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(Fig. 3-6D), and consistent levels of RT activity were observed in all treated cells (Fig. 3-
6C). In MDM cells, AP-3δ was efficiently depleted with treatment of siAP-3δ(1)-(4), 
whereas treatment with siAP-3δ(5) was less efficient by comparison (Fig. 3-6F). RT 
activity of the MDM supernatants was comparable for mock, siANC, and siAP-3δ(1)-(5) 
(Fig. 3-6E). These results indicate that virus production is inhibited in an AP-3δ-depleted 
manner but only in the setting of select AP-3δ-targeting siRNAs. 
Previous studies have demonstrated that the specificity of gene silencing by 
siRNA is reduced with increasing siRNA concentration, resulting in off-target effects 
(75, 135). In order to explore this possibility, we measured the level of virus production 
in cells treated with increasing concentrations of each siRNA. First, HeLa cells were 
treated with three 10-fold dilutions of each siRNA and assayed for AP-3δ expression. A 
dose-dependent depletion of AP-3δ was observed for each AP-3δ-specific siRNA, with 
siAP-3δ(5) being the least effective in depleting AP-3δ. (Fig. A2-4). To determine the 
individual effects of siAP-3δ(1)-(5)-mediated AP-3δ depletion on virus production, HeLa 
cells were mock-treated or treated with increasing concentrations of siANC, or each 
siAP-3δ(1)-(5). Cells were then infected with VSV-G/NL4-3Δenv, and cell supernatants 
and cells were harvested and analyzed. No significant differences in AP-3δ-depletion 
efficiency were observed in siAP-3δ(1)-(5)-treated cells, however the level of 
intracellular Gag expression in siAP-3δ(5)-treated cells was reduced (Fig. 3-7B). RT 
activity was minimally affected by siRNA concentration in siANC, siAP-3δ(1), and 
siAP-3δ(3)-treated cell supernatants, moderately affected in siAP-3δ(4)-treated cell 
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Figure 3-7. Effect of AP-3δ-specific siRNA concentration on HIV-1 production. 
HeLa cells were transfected with reagent alone (Mock), siANC (1 nM, 10 nM, 100 nM), 
and AP-3δ specific siRNAs: siAP-3δ(1)-(5) (1 nM, 10 nM, 100 nM). At 48 hours post 
transfection, cells were infected with VSV-G/NL4-3Δenv (MOI = 0.25). At 48 hours post 
infection, cell culture supernatants and cells were harvested. (A) Cell culture supernatants 
were analyzed for HIV-1 production by RT activity assay. Bars represent RT activity as 
mean percentages of mock ± SEM. Data shown is representative of two independent 
experiments performed in duplicate. The RT activities (counts per minute/10µL of 
supernatant) of the cell supernatants derived from mock-treated cells were: 5055.01 and 
14761.50. (B) Cell and viral lysates were analyzed by SDS-PAGE and Western blot with 
anti-AP-3δ, anti-p24, and anti-Sam68 antibodies.  
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supernatants and significantly affected in siAP-3δ(2) and siAP-3δ(5)-treated cell 
supernatants (Fig. 3-7A). The most pronounced inhibition of viral production was 
observed in siAP-3δ(5)-treated cell supernatants, where over 70% reduction in virus 
production was observed at the highest siRNA concentration tested. A negative dose-
dependence of p24 expression in viral lysates from siAP-3δ(2) and siAP-3δ(5)-treated 
cells was also observed (Fig. 3-7B). A negative dose-dependence of p24 expression in 
viral lysates from siAP-3δ(2) and siAP-3δ(5)-treated cells was also observed (Fig. 3-7B), 
and directly corresponded with RT activity.  
 
3.2.5. Disruption of AP-3 function by overexpressing AGAP1 does not affect HIV-1 
production 
 In addition to using an RNAi-based approach to study the role of AP-3 function in 
HIV-1 production, we also disrupted AP-3 function through the overexpression of its 
regulator, AGAP1 (Arf-GAP with GTP-ase domain, ankryin repeat, and pleckstrin 
homology domain 1). AGAP1 is an ADP ribosylation factor GTPase activating protein 
(ARF GAP) that specifically regulates ARF1 (ADP-ribosylation factor 1)-dependent 
recruitment of AP-3 to membranes by modulating the active state of ARF1 (112, 113). 
ARF1 is active and membrane associated when bound to GTP. Conversely, ARF1 is 
inactive and non-membrane associated when bound to GDP (38, 39). AGAP1 induces 
ARF1-mediated hydrolysis of GTP to GDP, resulting in ARF1 inactivation. Therefore, 
overexpression of AGAP1 increases the intracellular population of inactive GDP-bound 
ARF1, resulting in the inhibition of AP-3 recruitment to membranes and disruption of  
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Figure 3-8. Effect of wild-type or mutant AGAP1 overexpression on HIV-1 
production. HeLa cells were transfected with 0.5 µg or 1.0 µg of pHA-AGAP1[stop], 
pHA-AGAP1, or pHA-AGAP[R599K]. At 24 hours post-transfection, cells were infected 
with VSVG/NL4-3Δenv (MOI=0.25). At 48 hours post-infection, cell supernatants and 
cells were harvested. Cell culture supernatants were analyzed for HIV-1 production by 
RT activity assay (A and C). Bars represent RT activity as mean percentages of mock ± 
SEM. Data shown is representative of two independent experiments performed in 
duplicate (A) or three experiments (C). The RT activities (counts per minute/10µL of 
supernatant) of the cell supernatants derived from cells transfected with pHA-
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AGAP1[stop] were: 335.00 and 483.33 for 0.5 µg and 445.00 and 489.67 for 1.0 µg in 
(A). The RT activities (counts per minute/10µL of supernatant) of the cell supernatants 
derived from cells transfected with pHA-AGAP1[stop] in (C) were: 45811.04, 55815.72, 
and 57879.72 for 0.5 µg and 52238.07, 79850.12, and 76441.11 for 1.0 µg. (B and D) 
Cell and viral lysates were analyzed by SDS-PAGE and Western blot with anti-HA, anti-
p24, and anti-Sam68 antibodies.    
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AP-3 function. Conversely, overexpressing a GAP-inactive AGAP1 mutant does not 
affect AP-3 membrane association (112). To determine whether overexpression of 
AGAP1 affected virus production, HeLa cells were transfected with increasing 
concentrations of control vector pHA-AGAP1[stop], wild-type expression vector pHA-
AGAP1, or GAP-inactive mutant expression vector pHA-AGAP1[R599K]. At 24 hours 
post-transfection, cells were infected with VSV-G/NL4-3Δenv and cell supernatants and 
cells were harvested and analyzed 48 hours post-infection. Wild-type and mutant AGAP1 
expression increased in a dose-dependent manner while intracellular Gag levels remained 
constant (Figure 3-9B). We observed no significant differences in RT activity in cells 
transfected with pHA-AGAP1[stop], pHA-AGAP1 or pHA-AGAP1[599K] with either 
DNA concentration tested (Fig. 3-8A). The effect of wild-type or mutant AGAP1 
overexpression on AP-3 membrane binding was confirmed by indirect 
immunofluorescence (Chapter IV, Fig. 4-4B). These results indicate that overexpression 
of wild-type and mutant AGAP1 has no effect on virus production, suggesting that AP-3 
membrane association and function do not play a significant role in virus production. 
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3.3. Discussion 
In this study, we investigated the role of AP-3 in HIV-1 replication through two 
different approaches aimed at disrupting AP-3 function. In one approach, AP-3δ was 
depleted in infected HeLa, HeLa-LAV, and primary monocyte-derived macrophages. In 
another approach, AGAP1 was overexpressed in infected HeLa cells to inhibit AP-3 
association with membranes. We demonstrated using both strategies that AP-3 is not 
required for HIV-1 production, contrary to previous reports.  
We initially performed AP-3δ depletion studies using a single AP-3δ-specific 
siRNA to determine whether AP-3δ was required for virus production. We were able to 
efficiently and reproducibly deplete endogenous AP-3δ in a variety of cell types thereby 
permitting us to investigate virus production in an AP-3δ-deficient cellular environment. 
Unexpectedly, we observed that AP-3δ depletion had no effect on virus production in all 
cells tested including a natural target of HIV-1 (MDM) and chronically infected host 
(HeLa-LAV). HeLa cells were first tested to clarify previous reports implicating AP-3δ 
as an essential host factor for virus production in these cells. Our results contradict those 
studies and raise the possibility that HIV-1 replicates in an AP-3δ-independent manner. 
Concern over the sensitivity of our viral output measurements was addressed through 
hRIP depletion studies resulting in the expected inhibition of virus production (180). We 
next depleted AP-3δ in chronically infected HeLa-LAV cells, which enabled us to 
investigate the effect of AP-3δ depletion in cells where infection was already established. 
In this system, AP-3δ depletion again had no discernible effect on virus production. After 
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examining the role of AP-3δ in virus production in cells that promote virus production 
primarily at the plasma membrane, we wanted to determine whether AP-3δ would be 
required for virus production in primary human MDMs, which promote virus assembly 
primarily at MVBs. As AP-3δ has been implicated in mediating Gag trafficking to 
MVBs, MDMs provide the ideal experimental system to study this particular role of AP-
3δ. Surprisingly, AP-3δ was also found to dispensible for virus production in MDMs 
despite the prevalence of virus assembly at MVBs in these cells. Our results therefore 
bring into question whether AP-3δ truly mediates Gag trafficking to MVBs. Additionally, 
if AP-3δ does specifically mediate Gag trafficking to MVBs, our results question the 
overall significance of Gag trafficking to MVBs in virus production. 
To further demonstrate whether AP-3 was required for virus production, AP-3 
membrane association was disrupted by overexpressing AGAP1. Inhibition of AP-3 
membrane association requires the inactivation of ARF1, which can be induced with 
brefeldin A, a fungal metabolite that targets and inactivates ARF proteins (37, 143). A 
previous study using brefeldin A demonstrated that AP-3-membrane dissociation had no 
effect on virus production (80). However, the effect of brefeldin A cannot be solely 
attributed to AP-3, since ARF1 interacts with multiple coat proteins that would also be 
affected by brefeldin A treatment. Therefore, our studies exploiting disruption of AP-3 
recruitment to membranes through AGAP1 overexpression provides specificity to our 
approach (112-114). We demonstrated that overexpression of wild-type AGAP1 or GAP- 
inactive mutant AGAP1[R599K] had no effect on virus production, suggesting that AP-3 
membrane association and consequently its function, is not required for virus production. 
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Further investigation would be required to determine whether AP-3 mediates Gag 
targeting to MVBs, as we would expect Gag targeting to MVBs to be severely 
compromised in the setting of overexpressed AGAP1.  
Although our studies suggest that AP-3 is not required for HIV-1 production, we 
acknowledge that our findings directly dispute previous studies reported by Dong et al. 
and Camus et al. (20, 40). Based on our examination of a panel of unique AP-3δ-specific 
siRNAs, we suggest that the negative effect on virus production observed in previous 
studies are not attributed to AP-3δ depletion but are more likely a consequence of siRNA 
off-target effects. Two of the five siRNAs, siAP-3δ(2) and siAP-3δ(5), significantly 
inhibited virus production in an siRNA dose-dependent manner compared to three of the 
five siRNAs which exhibited little to no effect on virus production. The more potent 
inhibitor of virus production was siAP-3δ(5), which represents the one siRNA used in the 
Camus et al. study. siAP-3δ(2) represents one of the four pooled siRNAs used in the 
Dong et al. study and is therefore most likely responsible for the reported inhibitory 
phenotype seen with the siRNA pool; the three other siRNAs constituting the remainder 
of the pool had no effect in virus production. Considering that only one AP-3 silencing 
siRNA demonstrated a significant reduction in virus production, it is highly likely that an 
off-target effects of siAP-3δ(2) or siAP-3δ(5) are the primary mediators of viral 
inhibition rather than their on-target effect of AP-3 depletion. A dose-dependence in 
inhibition of viral production was observed in the context of siAP-3δ(2) and siAP-3δ(5) 
consistent with previous reports suggesting that off-target gene silencing by non-specific 
siRNAs occur in a dose-dependent manner. Alternatively, silencing of a second or 
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multitude of genes may act synergistically with AP-3 depletion to negatively affect 
productive HIV-1 replication. The observation that the off-target siRNAs were 
representative of the siRNAs used in both studies provides an explanation for the 
disparity between our results and the results of the two studies. Furthermore, our results 
highlight the importance of screening individual siRNAs designed against the same target 
to validate a phenotype with the associated depletion of a target.  
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CHAPTER IV: THE ROLE OF AP-3 IN HIV-1 GAG TRAFFICKING TO 
MULTIVESICULAR BODIES 
 
4.1. Introduction 
HIV-1 particle production begins with the targeting of the structural protein Gag 
to membranes, which serve as the sites of virus assembly. Gag is synthesized as a 
polyprotein precursor comprised of four domains: matrix (MA), capsid (CA), 
nucleocapsid (NC), and p6. During its translation on free cytoplasmic ribosomes, the MA 
domain of Gag is modified by the enzyme N-myristoyl transferase, resulting in the 
myristoylation of its N-terminus. The N-terminal myristate in addition to a highly basic 
region between residues 14 and 31 of MA, are required for Gag binding to membranes, as 
abrogation of myristoylation by mutating the N-terminal glycine residue, or mutating of 
the basic residues of the HBR leads to defects in Gag membrane binding and subsequent 
inhibition of particle production (17, 58, 122, 182). These findings implicate Gag binding 
to membranes as a requirement for subsequent virus assembly and particle production.  
Although the plasma membrane is considered to be the predominant site for Gag 
binding and virus assembly in most cell types (81, 173), Gag has also been demonstrated 
to associate with the limiting (outer) membrane of intracellular compartments known as 
multivesicular bodies (MVBs) (115, 154). In addition, virus budding into MVBs has been 
demonstrated to produce infectious particles (61, 132). However, the significance of the 
observed Gag:MVB association and its role in virus production has been a subject of 
debate. Studies have shown that targeting Gag to MVBs by introducing point mutations 
in MA, replacing the MA domain with membrane binding domains that have an affinity 
for endosomal membranes, or depleting cells of PI(4,5)P2 results in inhibited particle 
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production, suggesting that Gag targeting to MVBs may not be a productive process for 
viral replication. In addition, Gag association with MVBs has been shown to occur as a 
result of its endocytosis from the plasma membrane, which can be abolished without 
affecting virus production by inhibiting endocytosis or expressing Vpu (81, 107).  
Evidence for a productive role in Gag targeting to MVBs has been demonstrated 
in a study of Adaptor Protein Complex 3 (AP-3), which is currently the only Gag-
interacting cellular factor reported to be specifically involved in trafficking Gag to MVBs 
(40). We previously demonstrated that AP-3 does not play a role in virus production, 
which strongly suggests that AP-3δ-mediated Gag trafficking to MVBs is not essential 
for virus production (Chapter III). In this study, we investigated whether AP-3 plays a 
role in Gag trafficking to MVBs in HeLa cells, by observing Gag localization in AP-3δ-
depleted cells, or in the presence of overexpressed AGAP1, the regulator of AP-3. In 
addition, we examined the effect of AP-3δ depletion on the localization of a mutant form 
of Gag (GagK29E/K31E) that is specifically targeted to MVBs (120). Our results show that 
disruption of AP-3 function, either by depleting AP-3δ or by overexpressing AGAP1 
inhibited Gag trafficking to MVBs. However, GagK29E/K31E trafficking to MVBs was 
unaltered in the absence of AP-3δ. Collectively, these results indicate that AP-3 mediates 
wild-type Gag targeting to MVBs, but does not play a role in GagK29E/K31E targeting to 
MVBs, suggesting that wild-type and mutant Gag traffic to MVBs by different 
mechanisms. 
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4.2. Results 
4.2.1. HIV-1 Gag trafficking to MVBs is abrogated in the absence of AP-3δ 
 Disruption of the AP-3δ:Gag interaction by the overexpression of a dominant- 
negative AP-3δ mutant has previously been shown to inhibit Gag association with MVBs 
(40). However, Gag localization to MVBs has not been investigated in the absence of 
AP-3δ. In order to investigate the role of AP-3δ expression on Gag trafficking, we 
expressed a codon-optimized GFP-Gag in HeLa cells previously transfected with reagent 
alone (mock), siANC, or siAP-3δ(1). We first determined whether GFP-Gag co-localized 
with MVBs by staining mock-treated, GFP-Gag-expressing cells for endogenous MVB-
marker CD63 analyzed intracellular localization indirect immunofluorescence 
microscopy. We observed that GFP-Gag co-localized with CD63 and exhibited a 
punctate distribution that was concentrated near the perinucleus and exhibited an outward 
radiation (Fig. 4-1A). Mock, siANC, and siAP-3δ-treated, GFP-Gag-expressing cells 
were then stained for endogenous AP-3δ, to examine the intracellular localization of Gag 
in its presence or absence. In mock and siANC-treated cells, GFP-Gag exhibited similar 
localization patterns seen in the mock-treated GFP-Gag-expressing cells stained for 
CD63 (Fig. 4-1B, top and middle rows, respectively), suggesting that GFP-Gag is 
associated with MVBs in the presence of AP-3δ.  
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Figure 4-1. Effect of AP-3δ  depletion on intracellular Gag localization in HeLa cells. 
HeLa cells were transfected with reagent alone (mock), siANC, or siAP-3δ(1). At 48 
hours post-transfection, cells were transfected with pEGFP-CO-Gag and fixed 24 hours 
post-transfection. (A) Mock-treated GFP-Gag (green)-expressing cells were co-stained 
for endogenous CD63 (red) and the nucleus (blue) using an anti-CD63 antibody with an 
Alexa Fluor (AF) 594-conjugated secondary antibody and DAPI, respectively. (B) Mock 
(top row), siANC (middle row), and siAP-3δ(1) (bottom row)-treated GFP-Gag (green)-
expressing cells were co-stained for endogenous AP-3δ (red) and the nucleus (blue), 
using an anti-AP-3δ antibody with an AF594-conjugated secondary antibody and DAPI, 
respectively. Cells were analyzed by fluorescence microscopy. 
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In contrast, in siAP-3δ(1)-treated cells GFP-Gag exhibited a diffuse distribution 
throughout the cytoplasmthat extended to the cell periphery, with a slight accumulation at 
the cell periphery (Fig. 4-1B, bottom row). This indicated that GFP-Gag was not 
associated with intracellular membranes, and suggests that Gag trafficking to MVBs was 
inhibited in the absence of AP-3δ.  
To confirm these results, we next depleted AP-3δ using the panel of five siRNAs 
that were used in Chapter III to determine their effect on Gag to MVB trafficking. Gag-
GFP was expressed in cells previously treated with siANC or each of siAP-3δ(1)-(5), 
followed by staining for endogenous AP-3δ and analysis by indirect immunofluorescence 
microscopy. In siANC-treated cells, GFP-Gag exhibited a punctate intracellular 
distribution with some co-localization with AP-3δ, while in siAP-3δ(1)-(5)-treated cells, 
GFP-Gag exhibited a diffuse pattern with no apparent intracellular accumulation (Fig. 4-
2, rows 2-6). These results indicate that although siAP-3δ(1)-(5) exhibited differential 
effects on virus production, they exhibited the same effect on Gag localization due to 
their ability to downregulate AP-3δ. These results also suggest that the change in 
intracellular Gag localization is not attributed to the negative effects on virus production 
previously observed in siAP-3δ(2) and siAP-3δ(5)-treated cells (Chapter III).  
 We also investigated whether AP-3δ-depletion would affect Gag trafficking to 
MVBs in the chronically infected cell line, HeLa-LAV. HeLa-LAV cells were transfected 
with reagent alone (mock), siANC, or siAP-3δ(2). Mock-transfected cells were co-
stained for Gag and endogenous CD63 and analyzed by indirect immunofluorescence  
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Figure 4-2. Effect of AP-3δ  depletion on HIV-1 Gag localization using a panel of 
AP-3δ-specific siRNAs. HeLa cells were transfected with reagent alone (mock), siANC, 
or individually with siAP-3δ (1)-(5). At 48 hours post-transfection, cells were transfected 
with pEGFP-CO-Gag and fixed 24 hours post-transfection. GFP-Gag (green)-expressing 
cells were co-stained for endogenous AP-3δ (red) and the nucleus (blue), using an anti-
AP-3δ antibody with an AF594-conjugated secondary antibody and DAPI, respectively. 
Cells were analyzed by fluorescence microscopy. 
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Figure 4-3. Effect of AP-3δ  depletion on intracellular Gag localization in HeLa-LAV 
cells. HeLa-LAV cells were transfected with reagent alone (Mock), siANC, or siAP-
3δ(2). At 96 hours post-transfection, cells were fixed with methanol. (A) Mock-treated 
cells were co-stained for Gag (green), endogenous CD63 (red), and the nucleus (blue), 
using an anti-p24 primary antibody with an AF488-conjugated secondary antibody, an 
anti-CD63 primary antibody with an AF546-conjugated anti-mouse secondary antibody, 
and DAPI, respectively. (B) Mock, siANC, and siAP-3δ(2)-treated cells co-stained for 
Gag (green), endogenous AP-3δ (red), and the nucleus (blue), using an anti-p24 primary 
antibody with an AF488-conjugated secondary antibody, an anti-AP-3δ primary antibody 
with an AF546-conjugated anti-mouse secondary antibody, and DAPI, respectively. Cells 
were analyzed by fluorescence microscopy  
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microscopy. Gag co-localized with CD63 and exhibited a punctate, cytoplasmic 
distribution that was similar to what was observed in mock-treated, GFP-Gag-expressed 
HeLa cells (Fig. 4-3A), indicating that Gag was associated with MVBs. Mock, siANC, 
and siAP-3δ(2)-transfected cells were co-stained for Gag and endogenous AP-3δ, and 
analyzed by indirect immunofluorescence microscopy. Gag exhibited a punctate 
distribution in mock and siANC-treated cells, and exhibited some co-localization with 
AP-3δ (Fig. 4-3B, top and middle rows, respectively). However, in siAP-3δ(2)-treated 
cells, Gag exhibited a diffuse distribution throughout the cell with no apparent 
intracellular accumulation (Fig. 4-3B, bottom row), indicating that Gag association with 
MVBs was inhibited in the absence of AP-3δ. These results demonstrate that Gag 
localization to MVBs in chronically-infected HeLa-LAV cells is dependent on the AP-
3δ and parallel what we observed for GFP-Gag in HeLa cells.  
  
4.2.2. Overexpression of AGAP1 inhibits Gag trafficking to intracellular compartments  
 We also investigated whether disruption of AP-3 membrane association by 
overexpressing AGAP1, would have an effect on Gag trafficking to MVBs. GFP-Gag 
was expressed in HeLa cells previously transfected with control vector pHA-
AGAP1[stop], pHA-AGAP1, or pHA-AGAP1[R599K], which lacks GAP activity and 
does not disrupt AP-3 function (112). To observe the effect of wild-type and mutant HA-
AGAP1 on endogenous AP-3δ localization, GFP-Gag-expressing cells transfected with 
pHA-AGAP1 or pHA-AGAP1[R599K] were stained for endogenous AP-3δ and  
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Figure 4-4. Effect of the overexpression of wild-type or mutant AGAP1 on Gag 
localization. (A) HeLa cells were transfected with pHA-AGAP1, or pHA-
AGAP1[R599K] for 48 hours and were fixed 24 hours post-transfection. Cells were co-
stained for wild-type or mutant HA-tagged AGAP1 (red), endogenous AP-3δ (green), 
and the nucleus (blue), using an anti-HA primary antibody with an AF594-conjugated 
secondary antibody, an anti-AP-3δ primary antibody with an AF488-conjugated 
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secondary antibody, and DAPI, respectively. (B) HeLa cells were transfected with pHA-
AGAP1[stop] (top row), pHA-AGAP1 (middle row), or pHA-AGAP1[R599K] (bottom 
row). At 48 hours post-transfection, cells were transfected with pEGFP-CO-Gag and 
fixed 24 hours post-transfection. GFP-Gag (green)-expressing cells were co-stained for 
wild-type or mutant HA-tagged AGAP1 (red) and the nucleus (blue), using a rabbit anti-
HA primary antibody with an AF594-conjugated secondary, and DAPI, respectively. 
Cells were analyzed by fluorescence microscopy. 
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analyzed by indirect immunofluorescence microscopy. As expected, AP-3δ exhibited a 
diffuse intracellular distribution indicative of membrane dissociation in the presence of 
HA-AGAP1, but in the absence of HA-AGAP1 exhibited a punctate intracellular 
distribution indicative of membrane association (Fig. 4-3A, top row). However, AP-3δ 
distribution was unaffected by the overexpression of HA-AGAP1[R599K], which lacks 
GAP activity (Fig. 4-3A, bottom row). These results indicate that the overexpression of 
wild-type HA-AGAP1 specifically inhibits AP-3 intracellular membrane association, and 
is dependent on its GAP activity, which is consistent with previous reports (112, 113). 
We next analyzed GFP-Gag localization in cells transfected with pHA-AGAP1[stop], 
pHA-AGAP1, or pHA-AGAP1[599K] and stained for HA, by indirect 
immunofluorescence microscopy. In HA-AGAP1[stop] and HA-AGAP1[R599K]-
expressing cells, GFP-Gag exhibited a punctate intracellular distribution (Fig. 4-4B, top 
and bottom rows, respectively) resembling the intracellular distribution of CD63-stained, 
mock-treated cells from our earlier experiments (Fig. 4-1A). However, in cells that 
overexpressed HA-AGAP1, GFP-Gag exhibited a diffuse distribution throughout the 
cytoplasm, with minimal accumulation at the cell periphery (Fig. 4-4B, middle row). This 
observed Gag distribution was very similar to what we observed in AP-3δ-depleted cells 
(Fig. 4-1B), demonstrating that disruption of AP-3 function by overexpressing wild-type 
but not mutant AGAP1 inhibits Gag trafficking to intracellular compartments that are 
presumably MVBs, and corresponds with our previous observations in AP-3δ-depleted 
cells.  
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4.2.3. HIV-1 GagK29E/K31E trafficking to MVBs is AP-3δ-independent 
 We next investigated whether AP-3δ was required for mutant Gag (GagK29E/K31E) 
trafficking to MVBs. This Gag mutant associates with MVBs as a result of two K to E 
amino acid substitutions at residues 29 and 31 of MA (120) and is downstream of the AP-
3δ binding site. GFP-GagK29E/K31E was expressed in HeLa cells previously transfected 
with reagent alone (mock), siANC, or siAP-3δ(1). To determine whether GFP-
GagK29E/K31E co-localizes with MVBs, mock-transfected cells were stained for CD63 and 
analyzed by indirect immunofluorescence microscopy. We observed that GFP-
GagK29E/K31E was concentrated at the perinuclear region and co-localized with MVBs that 
appeared larger than what we previously observed in HeLa and HeLa-LAV cells (Fig. 4-
4A). We next examined the localization of GagK29E/K31E-GFP in mock, siANC, or siAP-
3δ(1)-treated cells stained for endogenous AP-3δ. GagK29E/K31E-GFP exhibited punctate 
clusters around the perinucleus presumably associated with MVBs all cells treated (Fig. 
4-4B, top, middle, and bottom rows, respectively), indicating that Gag localization to 
these compartments is not dependent on AP-3δ.  
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Figure 4-5. Effect of AP-3δ  depletion on mutant GagK29E/K31 localization. 
HeLa cells were transfected with reagent alone (Mock), siANC, or siAP-3δ(1). At 48 
hours post-transfection, cells transfected with pEGFP-CO-GagK29E/K31E and fixed 24 
hours post-transfection. (A) Mock-treated GFP-GagK29E/K31E (green)-expressing cells 
were co-stained for endogenous CD63 (red) and the nucleus (blue) using an anti-CD63 
primary antibody with an AF594-conjugated secondary antibody and DAPI, respectively. 
(B) Mock (top row), siANC (middle row), and siAP-3δ(1) (bottom row)-treated GFP-
GagK29E/K31E (green)-expressing cells were co-stained for endogenous AP-3δ (red) and 
the nucleus (blue), using an anti-AP-3δ antibody with an AF594-conjugated secondary 
antibody and DAPI, respectively. Cells were analyzed by fluorescence microscopy.  
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4.3 Discussion 
  In this study, we used previously unexplored strategies to investigate whether 
AP-3 plays a role in Gag trafficking to MVBs. We examined wild-type Gag localization 
in AP-3δ-depleted cells and in AGAP1-overexpressing cells, which disrupted AP-3 
membrane binding. In addition, the localization of a Gag mutant with mutations in MA 
that targets Gag specifically to MVBs was examined in AP-3δ-depleted cells. Through 
these studies, we demonstrated that AP-3 is involved in Gag trafficking to MVBs.  
AP-3δ, which directly interacts with the MA domain of Gag, has previously been 
implicated in targeting Gag to MVBs (40). This was demonstrated by overexpressing an 
AP-3δ dominant-negative (DN) mutant thought to disrupt the AP-3δ:Gag interaction 
(40). However, this approach relied on the assumption that the only function of the AP-3δ 
DN mutant in the presence of Gag would be to inhibit the AP-3δ:Gag interaction. It is 
possible that the AP-3δ DN mutant itself mislocalized Gag, or prevented the interaction 
between Gag and another cellular factor that potentially mediated Gag trafficking to 
MVBs. Therefore, we used a direct approach to study the role of AP-3δ in Gag 
trafficking to MVBs by examining Gag localization in AP-3δ-depleted cells. AP-3δ-
deficiency resulted in a diffuse cytoplasmic distribution of Gag with no apparent 
intracellular accumulation. In contrast, Gag distribution was punctate and co-localized 
with MVB-marker CD63 in the presence of AP-3δ. Additionally, this effect on Gag 
localization was observed in cells that were individually treated with the five different 
AP-3δ-specific siRNAs, siAP-3δ(1)-(5), previously described in Chapter III. The 
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demonstration that treatment with each of the five AP-3δ-specific siRNAs resulted in 
similar Gag localization phenotypes strongly implicates AP-3δ in mediating Gag 
localization to MVBs. While we previously observed off-target effects on virus 
production associated with siAP-3δ(2) and siAP-3δ(5) treatment, these siRNAs affected 
Gag localization similarly to siAP-3δ(1), (3), and (4), suggesting that intracellular 
redistribution of Gag does not contribute to the reduction in virus production associated 
with siAP-3δ(2) and siAP-3δ(5) treatment. We observed a similar effect on Gag 
localization in the absence of AP-3δ in chronically infected HeLa-LAV cells, 
demonstrating that the observed change in Gag distribution is attributable to AP-3δ 
depletion. The similar intracellular distributions of GFP-Gag and virally-expressed Gag 
also demonstrate that Gag adopts the same localization pattern independent of its mode of 
expression.  
AP-3-mediated protein transport to MVBs is initiated by its recruitment to 
membranes, which gives rise to the formation of AP-3-coated vesicles on which protein 
cargo is bound and trafficked to MVBs. Therefore, disrupting AP-3 recruitment to 
membranes inhibits all downstream functions of AP-3 and prevents AP-3-mediated 
trafficking of protein cargo to MVBs. We used a specific approach to inhibit AP-3 
membrane binding by overexpressing its regulator, AGAP1, which disrupted AP-3 
membrane association and Gag localization to MVBs. Gag localization to MVBs 
occurred in cells expressing the GAP-inactive AGAP1 mutant, demonstrating the 
specificity of the observed Gag localization phenotype associated with AGAP1 
overexpression. The observed change in Gag localization in the presence of 
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overexpressed AGAP1 was similarly observed in AP-3δ cells, suggesting that Gag 
utilizes AP-3-mediated transport for its localization to MVBs.  
A previously characterized Gag mutant, GagK29E/K31E, has been reported to 
specifically traffic to MVBs by an unknown mechanism (120). Based on our findings that 
AP-3 mediates wild-type Gag trafficking to MVBs, we hypothesized that AP-3 also 
mediated the trafficking of GagK29E/K31E to MVBs. However GagK29E/K31E localization to 
MVBs was unaltered in AP-3δ-depleted cells, suggesting that GagK29E/K31E traffics to 
MVBs by an AP-3δ-independent mechanism. This could be explained by the differences 
in distribution observed between the mutant and wild-type Gag. GagK29E/K31E associated 
with MVBs in perinuclear clusters that were larger than the MVB compartments 
observed in wild-type Gag-expressing cells. Additionally, the effect on the morphology 
of the MVBs appears to be mediated by GagK29E/K31E, as neighboring cells that did not 
express GagK29E/K31E exhibited normal MVB distribution and morphology. Wild-type Gag 
exhibited a punctate distribution that appeared to concentrate near perinuclear regions 
and gradually spread out towards the cell periphery, suggesting directionality or 
movement. In contrast, GagK29E/K31E was localized mainly at the perinuclear region, 
suggesting that Gag and the MVBs may be static. As expression of GagK29E/K31E in the 
context of proviral clone pNL4-3 has been reported to inhibit virus production in HeLa 
cells, the GagK29E/K31E-associated decline in virus production may be explained by the 
possible immobilization of GagK29E/K31E-associated MVBs. This could suggest that Gag-
associated MVBs require exocytosis to deliver their viral contents to the extracellular 
space, which appears to be inhibited in the presence of the K to E mutations in MA. The 
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demonstration that Gag targeting to MVBs can occur by an AP-3-independent 
mechanism suggests that other determinants are involved in mediating Gag targeting to 
MVBs. It is possible that the K to E substitutions disrupted the MA:AP-3δ interaction for 
which Gag compensated by using another mechanism to traffic to MVBs.   
Although our studies demonstrate that wild-type Gag is dependent on AP-3 for its 
association with MVBs, it is unclear whether Gag is directly trafficked to the MVBs or 
localizes to MVBs as a result of endocytosis. Determining the origin of Gag that 
associates with MVBs would aid in understanding the overall significance of this 
association in viral replication. Direct Gag targeting to MVBs could demonstrate that this 
process contributes to virus production, while indirect Gag targeting to MVBs as a result 
of its endocytosis could demonstrate that this process does not play a significant role in 
virus production. As there are two mechanisms by which AP-3 mediates direct and 
indirect protein trafficking to MVBs (73), further investigation to delineate the specific 
trafficking pathway would be required to determine the origin of Gag in these 
compartments.  
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CHAPTER V: SUMMARY AND GENERAL DISCUSSION 
 
Summary of Results 
The work presented in this thesis demonstrated that AP-3 is not required for HIV-
1 replication, but is required for trafficking Gag to multivesicular bodies, indicating that 
AP-3δ-mediated Gag trafficking to MVBs does not play a productive role in HIV-1 
replication. We demonstrated through efficient and reproducible depletion of endogenous 
AP-3δ in infected HeLa, HeLa-LAV, and primary MDM cells that AP-3δ expression is 
not required for HIV-1 replication. AP-3δ depletion also did not affect infectious particle 
production or permissiveness to infection. The inhibition of AP-3 membrane association 
by overexpression of AGAP1 was also demonstrated to have no effect on HIV-1 
replication in infected HeLa cells. An examination of the individual effects of five 
different AP-3δ-specific siRNAs on virus replication revealed the existence of two 
different phenotypes associated with siRNA treatment, either having no effect on or 
severely inhibiting virus production. Further investigation demonstrated that the 
inhibitory effect on virus production by two siRNAs could not be solely attributed to AP-
3δ depletion, as the remaining three siRNAs depleted AP-3δ with the same efficiency 
without significantly affecting virus production. These results provided validation for 
previous results, which demonstrated that AP-3δ is not required for HIV-1 production. In 
addition, we demonstrated that Gag trafficking to MVBs was inhibited in the absence of 
AP-3δ or when AGAP1-mediated AP-3 membrane association was disrupted. However, 
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this was not apparent for mutant GagK29E/K31E, as its trafficking to MVBs was not affected 
by AP-3δ depletion.  
 
General Discussion 
Gag Trafficking to Multivesicular Bodies and HIV-1 Replication 
Our studies demonstrate that Gag is trafficked to MVBs in an AP-3δ-dependent 
manner that is dispensable for HIV-1 replication. While the observation that 
demonstrated that AP-3δ is required for localization of Gag to MVBs is in support of the 
original study by Dong et al, our conclusion that AP-3δ is not required for HIV-1 
replication directly contradicts their assertions regarding the role of AP-3δ in HIV-1 
replication. Dong et al. proposed a model in which AP-3δ-mediated Gag trafficking to 
MVBs provides Gag with access to the ESCRT machinery, which it redirects to the 
plasma membrane by an unknown mechanism. The observations that virus particle 
production was severely compromised by the depletion of AP-3δ or the disruption of the 
AP-3δ:MA interaction suggest that Gag trafficking to MVBs and its subsequent targeting 
to the plasma membrane is the primary pathway used by Gag during the process of 
particle production. However, this model does not fit with our results as well as those 
from previous studies. The rationale for the association of Gag with MVBs to acquire the 
ESCRT machinery assumes that MVBs are the only sites where Gag can acquire ESCRT. 
Although ESCRT is primarily known for its role in MVB biogenesis and sorting mono-
ubiquitinated cargo into MVBs for subsequent cargo degradation, it has been implicated 
in additional biological processes including cytokinetic abscission, autophagy, mRNA 
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transport, and RNAi-mediated mRNA silencing (149). Thus, these multiple functions 
would require ESCRT to be localized at multiple intracellular sites and could be acquired 
by Gag in a non-MVB context.  To address the assertion that AP-3δ-mediated Gag 
trafficking to MVBs is required for virus production has been demonstrated by our work, 
which indicates that AP-3δ is not required for virus production. Several lines of evidence 
also demonstrate that virus production occurs without the need for Gag association with 
MVBs. Although a live imaging study of newly synthesized Gag demonstrated that it 
trafficked to MVBs prior to its localization to the plasma membrane (134), a similar 
study demonstrated that newly synthesized Gag trafficked directly to the plasma 
membrane without associating with MVBs (148). A temporal study of Gag distribution 
also demonstrated that Gag trafficked directly to the plasma membrane, which promoted 
robust virus production (81). Additionally, this study demonstrated that Gag localization 
to MVBs occurred at later time points as a result of its endocytosis from the plasma 
membrane. Furthermore, inhibiting endocytosis abrogated Gag localization to MVBs, 
while having no effect on virus production (81). In the presence of Vpu, which prevents 
the endocytosis of virus particles through its antagonization of Tetherin, Gag localization 
to MVBs is absent, but occurs in the absence of Vpu (107). These results strongly suggest 
that Gag targeting to MVBs is not a productive pathway for HIV-1 replication, and 
appears to be an artifact of endocytosis. In some cases, Gag targeting to MVBs has been 
demonstrated to be inhibitory for virus production. Studies in which Gag was targeted to 
MVBs by altering its affinity for the plasma membrane inhibits virus particle production 
in 293T cells, HeLa cells, and macrophages (81). Collectively, these results strongly 
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suggest that Gag trafficking to MVBs is not a productive pathway for HIV-1 replication 
and in can actually be detrimental for virus replication, therefore challenging the 
implication that Gag trafficking to MVBs plays a critical role in viral replication. In 
addition, these results also indicate that AP-3δ does not play a productive role in viral 
replication.  
  
siRNA Off-Target Effects  
The use of siRNAs to specifically silence a particular gene of interest has proven 
to be a powerful tool in understanding the role of expressed genes in biological processes. 
However, siRNAs have also been demonstrated to concomitantly induce specific and 
non-specific gene silencing  resulting in off-target related phenotypes (75, 135). Through 
a study of five different AP-3δ-specific siRNAs, we identified three siRNAs that 
exhibited no effect on virus production and two siRNAs that exhibited inhibitory effects 
on virus production. All five siRNAs efficiently depleted AP-3δ, suggesting that the 
inhibitory effect on virus production could not be solely attributed to AP-3δ depletion. 
The inhibitory effect of the two siRNAs was more pronounced with a dose at which off-
target effects are frequently observed (81). The two siRNAs, siAP-3δ(2) and siAP-3δ(5), 
shared the same target sequence as the siRNAs used in the Dong et al. and Camus et al. 
studies, respectively. These results strongly suggest that the virus inhibition observed in 
the two studies was not a result of AP-3δ depletion alone, but was mediated by off-target 
effects of the particular siRNAs used in their studies. Further analysis of the target 
regions of all five siRNAs by a BLAST (basic local alignment search tool) search 
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revealed that the target sequences of siAP-3δ(1), siAP-3δ(4), and siAP-3δ(3), which did 
not exhibit significant inhibitory effects on virus production, shared 15/19 nucleotide (nt) 
homology to 0, 0, or 1 cDNA (homeobox B8, HOXB8), respectively. In contrast, siAP-
3δ(2) and siAP-3δ(5) each shared 15/19 nucleotide (nt) homology with two (plant 
homeodomain finger protein 2 (PHF2) and POM121) or three (solute carrier family 38, 
member 9 (SLC38A9), GATA5, and Epstein-Barr Virus Induced 3 (EBI3)/IL-27B) other 
cDNAs, respectively (Figure 5-1). Stringent siRNA design typically eliminates putative 
target regions that share 15/19 nt sequence homology with any other target, therefore it is 
unusual that these siRNAs were selected for use in experimentation. These observations 
further support the possibility that siAP-3δ(2) and siAP-3δ(5) exhibit off-target silencing 
effects. It is evident through our study that stringent siRNA design and validation of 
siRNA-associated phenotypes should have been performed to avoid the incorrect 
assessment that AP-3δ plays a significant role in virus production.  
 
The site of virus assembly in macrophages: revisited 
The primary function of macrophages is to phagocytose surrounding pathogens, 
cells, and debris, and as a result they require an active endosomal-lysosomal sorting 
system (7). As AP-3δ functions in the endosomal-lysosomal system and was reported to 
play a role in HIV-1 replication by directing Gag to MVBs, we hypothesized that AP-
3δ-mediated Gag trafficking to MVBs would play a significant role in HIV-1 replication 
in macrophages. During the course of our study, AP-3δ was reported to be required for 
mediating Gag trafficking to a tetraspanin-rich compartment in dendritic cells (DC) viral 
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Figure 5-1. AP-3δ-specific siRNA target sequence BLAST results. Bars represent the 
number of genes with 15 of 19 nucleotide homology to the AP-3δ-specific siRNA target 
sequences tested, as determined by basic local alignment search tool (BLAST). 
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replication, which provided some support for our hypothesis. Therefore, we were 
surprised at our finding that virus production in macrophages was not affected by AP-3δ 
depletion. The differences in function between DCs and macrophages may account for 
the differences in phenotypes observed, however without having studied the role of AP-
3δ in these cells we cannot make a direct comparison between our results and the results 
of the DC study.  
However, our results in macrophages could be explained by recent studies that 
have suggested that the intracellular virus assembly compartments have been 
misidentified as MVBs and are actually deep invaginations of the plasma membrane (34, 
173). This was demonstrated through ultrastructural studies of infected macrophages that 
were stained with the membrane-impermeant dye, ruthenium red (RR) (34, 173). 
Apparently intracellular VCCs were positively-stained with RR (RR+) suggesting that 
they were connected to the plasma membrane. In addition, the RR+ VCCs were devoid of 
endosomal markers, suggesting that the VCCs were not of endosomal origin but did co-
stain with the plasma membrane marker CD44. Furthermore, extracellular virions derived 
from infected macrophages precipitated with CD44, indicating that CD44 was 
incorporated into viral membranes as a result of budding from the plasma membrane 
(173). A study that used ion-abrasion scanning electron microscopy demonstrated that the 
VCCs are connected to the plasma membrane by tubules that allow sequestered viruses to 
access the extracellular space (8). The authors of this study suggested that the use of 
sectioned specimens with conventional transmission scanning electron microscopy 
provides an incomplete picture, which could have contributed to the misidentification of 
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intracellular compartments as MVBs instead of invaginations of the plasma membrane. 
Rapid movement of Gag from VCCs connected to the cell:cell synapse in the presence of 
uninfected T-cells has been observed in live-cell imaging studies of infected 
macrophages demonstrating that Gag may traffic along these plasma membrane-
connected tubules (59). Interestingly, an ultrastructural study comparing in vitro versus in 
vivo infected macrophages revealed a striking difference in viral assembly sites. In in 
vitro infected macrophages virus particles were often observed in MVBs, however in in 
vivo infected macrophages (ie. macrophages isolated from HIV-1 infected individuals) 
the vast majority of virus assembly occurred at the plasma membrane and was rarely 
observed in MVBs (125). Taken together, these results demonstrate the possibility that in 
macrophages, the MVB is not the intracellular site once thought to promote virus 
assembly, which would obviate AP-3δ-mediated Gag trafficking to this compartment.   
 
A model for AP-3-mediated Gag Trafficking To MVBs and its role in virus replication 
AP-3 mediates the trafficking of proteins that are destined for lysosomes by 
initially transporting protein cargo to MVBs, which deliver the cargo to lysosomes upon 
the fusion of the two compartments (33, 89). Protein cargo typically binds to the µ 
subunit of AP-3 or the AP-3 σ-δ hemicomplex through tyrosine or dileucine motifs, 
respectively (74, 76). Therefore, it is interesting that Gag interacts with the hinge region 
of AP-3δ, a region of the subunit that is not typically used for cargo recognition. In 
addition, although Gag encodes a dileucine motif and tyrosine motifs, they are not 
present within the AP-3δ binding site of MA. As it would seem nonsensical for Gag to be 
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a willing participant in a degradative pathway to the lysosome, it is possible that binding 
AP-3δ non-canonically would aid in the circumvention of its delivery to lysosomes. To 
date, only two other proteins known to bind the hinge region of AP-3δ have been 
identified. One of the proteins is the glycoprotein of the Vesicular Stomatitis Virus 
(VSV-G), which is atypically trafficked by AP-3 directly to the plasma membrane from 
the trans-Golgi network (TGN) through the secretory pathway. The other protein, cellular 
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) VAMP7 
(vesicle associated membrane protein 7), undergoes AP-3-mediated transport along the 
canonical trafficking pathway from early endosomes to MVBs. However, in addition to 
fusing with lysosomes, VAMP7-associated MVBs also undergo exocytosis via VAMP7-
mediated fusion with the plasma membrane, subsequently releasing the MVB contents 
into the extracellular space as exosomes (reviewed in (23). By binding non-canonically to 
the AP-3δ hinge region, VAMP7 does not compete with standard cargo, thus enabling 
AP-3 to bind more than one cargo at a time (85). A recent study has reported that the 
HIV-1 Nef protein is released from cells in exosomes (92), providing evidence that this 
mode of release is used by another viral protein. Virus containing MVBs have been 
shown to fuse with lysosomes and the plasma membrane (125), suggesting that Gag does 
not discriminate between these MVBs. In addition, although exocytosed assembled virus 
particles could contribute to productive HIV-1 replication, our data suggests that this is 
not the primary route by which Gag traffics to the plasma membrane.   
Based on these observations, previous studies suggesting that Gag or virions 
localize to the MVB as a result of endocytosis, and our demonstration that AP-3δ 
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mediates Gag trafficking to MVBs but is not required for HIV-1 replication, we have 
developed a model to describe the intracellular routes of Gag and their roles in HIV-1 
replication. In this model (Fig. 5-2), Gag undergoes AP-3δ-mediated trafficking to MVBs 
directly or as a result of endocytosis and is either delivered to the lysosome for 
degradation or released into the extracellular space via exocytosis. Gag is also targeted to 
the plasma membrane by an AP-3 independent mechanism, which is the predominant 
pathway for viral assembly. In the absence of AP-3δ, Gag trafficking to MVBs is 
inhibited, while its trafficking to the plasma membrane remains intact. As a result, Gag 
that would have been trafficked by AP-3 to MVBs is available to traffic to the plasma 
membrane where it promotes virus assembly. Therefore, no discernible difference in 
virus production would be observed between AP-3δ expressing and non-expressing cells.  
 
Future Directions 
Work presented in this thesis aimed to extend previous work on the role of AP-3 
in HIV-1 replication. While we demonstrated that AP-3δ was not required for HIV-1 
replication in the cells tested, there are still areas that warrant further investigation. As we 
established that AP-3δ mediates Gag trafficking to MVBs in HeLa and chronically 
infected HeLa-LAV cells, we do not yet know the role of AP-3δ on the intracellular  
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Figure 5-2. A model for AP-3-dependent Gag trafficking and HIV-1 production. 
(Left) Gag undergoes AP-3δ-mediated trafficking to MVBs directly or as a result of 
endocytosis and is subsequently delivered to the lysosome for degradation, or is released 
into the extracellular space via exocytosis. Upon MVB fusion with the plasma membrane, 
internalized virus particles are released into the extracellular space. Gag that is 
unassociated with AP-3δ traffics directly to the plasma membrane, the predominant site 
of virus assembly and release. (Right) In AP-3δ-deficient cells, Gag is exclusively 
trafficked directly to the plasma membrane resulting in virus assembly and release.  
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localization of Gag in MDMs. The intracellular virus assembly site in MDMs is 
suggested to be plasma membrane-derived instead of endosomal. Therefore, it would be 
even more interesting to observe the intracellular site that AP-3δ traffics Gag, if it does 
indeed play a role in Gag trafficking in this cell type. Given that virus assembly has been 
observed at tetraspanin-rich domains in dendritic cells and AP-3δ has been implicated in 
trafficking Gag to these sites (52), it is possible that a similar site is used by Gag in 
MDMs.   
As the role of AP-3δ in cells that predominantly promote virus assembly at the 
plasma membrane has been limited to investigation in HeLa and 293T cells, future 
investigation in T-cells would provide insight into whether AP-3δ plays a functional role 
in these cells, which are the major target of HIV-1. As virus assembly has been observed 
in the MVBs of T-cell lines (61), which would require Gag targeting to these intracellular 
compartments, it is possible that AP-3δ is responsible for this localization. In addition, 
determining the role of AP-3δ function on HIV-1 replication would provide much needed 
aid in clarifying whether Gag targeting to MVBs is truly a significant contributor to viral 
replication, a subject that has caused much controversy in this area of HIV-1 research.  
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APPENDIX I: DEVELOPMENT OF AN MS2-BASED REPORTER CONSTRUCT 
TO VISUALIZE HIV-1 GENOMIC RNA TRAFFICKING IN LIVING CELLS 
 
Introduction 
 HIV-1 genomic RNA is an essential component of HIV-1 virus particles and 
plays a number of essential roles in the viral life cycle. During the late stage of viral 
replication, gRNA is localized to virus assembly and is incorporated into nascent virions 
by the NC domain of Gag (10). This NC:gRNA is mediated by the two zinc-fingers of the 
NC domain and the gRNA packaging signal, which is only present in gRNA and provides 
specificity for the viral incorporation of this particular RNA. Although the determinants 
for gRNA packaging have been well characterized, the intracellular route taken by gRNA 
is not well understood.  
As gRNA trafficking is likely to be a dynamic process, live-cell imaging 
techniques would be required to study the movement of gRNA. One method to detect 
RNA in living cells exploits the elements of the bacteriophage, MS2, to selectively tag 
the RNA of interest with a GFP-tagged protein (reviewed in (142, 146)). The MS2 coat 
protein binds with high affinity and specificity to a 19 nt stem loop in the genomic RNA 
of MS2 and directs its packaging into phage particles, which is analogous to NC binding 
to the packaging signal of the gRNA of HIV-1. These stem loops can be cloned in 
tandem into cDNA that encodes the RNA of interest, thus providing binding sites for the 
MS2 coat protein to bind. Fusion of the MS2 with the fluorescent protein, GFP, allows 
for the tracking of the MS2-GFP-bound RNA of interest in living cells. 
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Subgenomic HIV-1 constructs have been developed and used as a surrogate for 
bona fide gRNA (82, 105), however, a full-length gRNA reporter has not been 
developed. In this study, we have constructed a gRNA reporter from pNL4-3 that 
contains 24 tandem MS2 binding sites within the integrase open-reading frame and 
characterized its ability to produce virus particles, incorporation into nascent virions, and 
intracellular localization.  
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Figure A1-1. Schematic representation of the MS2 Reporter System. Tandem MS2 
binding sites integrated into the RNA of interest are bound by the MS2-GFP fusion 
protein, which binds to each stem loop as a dimer. GFP fused to the MS2 protein allows 
for the visualization of the MS2-GFP-bound RNA in living cells.  
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Materials and Methods 
Constructs 
pNL4-3-Rd4: a pNL4-3 derivative with ablated BamHI and SphI sites in gag and env  
which were reintroduced into the integrase open reading frame. This construct 
was generated by four successive rounds of site-directed mutagenesis, using the 
QuikChange site-directed mutagenesis kit (Stratagene). For the first round, pNL4-
3 was used as the template and the resulting PCR product was used as the 
template for the next round, and so on, until the fourth round was completed. The 
following oligos were used: 
(ALK51+/- were used to ablate the SphI site at nt 1447 of pNL4-3) 
ALK51+: 5’GATTGCATCCAGTCCACGCAGGGCCTATTG3’ 
ALK51-:  5’CAATAGGCCCTGCGTGGACTGGATGCAATC3’ 
(ALK52+/- were used to ablate the BamHI site at nt 8465 of pNL4-3) 
ALK52+: 5’CGATTAGTGAACGCATTCTTAGCACTTATC3’ 
ALK52-:  5’GATAAGTGCTAAGAATGCGTTCACTAATCG3’ 
 
(ALK53+/- were used to generate a BamHI site at nt 4370 of pNL4-3) 
ALK53+: 5’GCTAAAAGGGGATCCCATGCATGGAC3’ 
ALK53-:  5’GTCCATGCATGGGATCCCCTTTTAGC3’ 
(ALK54.1+/- were used to generate a SphI site at nt 4764 of pNL4-3) 
ALK54.1+: 5’GACAGCAGTACAAATGGCATGCTTCATCCAC3’ 
ALK54.1-:  5’GTGGATGAAGCATGCCATTTGTACTGCTGTC3’  
pNL4-3-MS2-6: a pNL4-3 derivative with 6xMS2 binding sites isolated from pSL-MS2- 
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6X cloned into the BamHI and SphI sites of pNL4-3-Rd4  
pNL4-3-MS2-12: a pNL4-3 derivative with 12xMS2 binding sites isolated from pSL- 
MS2-12X cloned into the BamHI and SphI sites of pNL4-3-Rd4 
pNL4-3-MS2-24: a pNL4-3 derivative with 24xMS2 binding sites isolated from pSL- 
MS2-24X cloned into the BamHI and SphI sites of pNL4-3-Rd4  
pSL-MS2-6X: an expression vector containing 6 tandem MS2 binding sites (received  
from Dr. Robert Singer) 
pSL-MS2-12X: an expression vector containing 12 tandem MS2 binding sites (received  
from Dr. Robert Singer) 
pSL-MS2-24X: an expression vector containing 24 tandem MS2 binding sites (received  
from Dr. Robert Singer) 
 
Fluorescence In Situ Hybridization 
Cells mounted onto coverslips were fixed with 2% paraformaldehyde/5mM 
MgCl2 followed by incubation in hybridization solution: 30% formamide, 0.2X saline-
sodium citrate, 1mg/mL bovine serum albumin, 10% dextran sulfate, and 0.1 mg/mL 
herring sperm DNA for 1 hour at 37°C. Coverslips were incubated with a Cy-3 labeled 
gag-pol DNA probe in the hybridization solution for 1 hour at 37C. Coverslips were 
drained and incubated twice in hybridization solution for 30 minutes at 37°C. Coverslips 
were washed in 20% formamide/2XSSC for 30 minutes at room temperature, once in 
20% formamide/1XSSC for 15 minutes at room temperature, and twice with 1XSSC for 
15 minutes at room temperature. Cells were stained with DAPI (1:10000) of a 1 µg/µL 
 107 
stock and coverslips were mounted onto glass slides using Prolong Gold Anti-fade 
reagent (Invitrogen). Cells were visualized using a Zeiss Axioplan 2 fluorescence 
microscope equipped with a 63× plan Apochromat objective. Images were acquired and 
analyzed using Open Lab 2.2.5 software.  
 
RT-PCR 
RNA was purified from 1 mL of cell supernatants using the QIAamp UltraSens 
Virus Kit (Qiagen) following the manufacturer’s protocol. The RNA was treated with 
RQ1 RNase-free DNase (Promega) prior to RT-PCR. First-strand cDNA synthesis was 
performed using the SuperScript II RT Kit (Invitrogen) according to the manufacturer’s 
protocol, the DNase-treated RNA and reverse primer ALK-RT1(-). Following first-strand 
synthesis, PCR was performed using the cDNA from the first-strand reaction and the 
following oligos: ALK-RT1(-) and ALK-RT(+).  
ALK-RT1(-): 5’CTTTAGTTTGTATGTCTGTTG3’ 
ALK-RT1(+):5’GTGCTGGAATCAGGAAAGTAC3’ 
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Results 
Cloning Strategy 
 In order to specifically tag gRNA while keeping the required viral genes intact, 
we chose to insert the MS2 binding sites into the integrase open reading frame. Typically, 
24 MS2 binding sites are inserted into the cDNA of interest to provide more sites for 
MS2-GFP to bind and thus maximize signal intensity. The addition of 24 MS2 binding 
sites in gRNA would increase its overall length and possibly prevent its incorporation 
into virions. Therefore, generated three different constructs by inserting either 6, 12, or 
24 MS2 binding sites into the integrase open reading frame. In order to insert the binding 
sites, we first introduced silent mutations in the original BamHI and SphI sites in pNL4-3 
to destroy the sites. Next, we introduced the BamHI and SphI sites into the desired 
regions of the integrase open reading frame. These mutations required four different 
rounds of site-directed mutagenesis by PCR, and therefore this construct was referred to 
as pNL4-3-Rd4. The 6, 12, and 24 binding sites were cloned into the BamHI and SphI 
sites in pNL4-3-Rd4 to generate pNL4-3-MS2-6 (pN-M-6), pNL4-3-MS2-12 (pN-M-12), 
and pNL4-3-MS2-24 (pN-M-24), respectively. A schematic detailing the cloning strategy 
is shown in Figure A1-1.  
 
MS2-containing gRNAs produce virus particles 
  To determine whether the generated clones could produce virus particles, pNL4-
3-Rd4, pN-M-6, pN-M-12, and pN-M-24 were transfected into HeLa cells. Cell  
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Figure A1-2. Schematic representation of the cloning strategy used to generate the 
MS2 reporter constructs. The original BamHI and SphI sites in pNL4-3 were ablated 
and new BamHI and SphI sites were generated in the integrase open reading frame. 
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Figure A1-3. NL43-MS2 constructs produce virus. HeLa cells were transfected with 2 
µg of pNL43-Rd4, pNL43-MS2-6, pNL43-MS2-12, or pNL43-MS2-24. At 48 hours 
post-transfection, cell supernatants and cells were harvested. (A) Cell supernatants were 
assayed for virus production by RT activity. Bars represent RT activity. (B) Cell lysates 
were assayed for Gag expression by SDS-PAGE and Western blot using an anti-p24 
antibody.  
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supernatants and cells were assayed for virus production and protein expression, 
respectively. Interestingly, RT activity inversely correlated with the number of binding 
sites present in the constructs (Fig. A1-2A), which was also reflected by intracellular Gag 
expression (Fig. A1-2B). Although the constructs produced virus particles, the overall 
production was low in comparison to NL4-3-Rd4.  
 
MS2 gRNA is incorporated into virions 
 We next determined whether the MS2-containing gRNA constructs could be 
packaged into virus particles. HeLa cells were transfected with pNL4-3, pNL4-3-Rd4, 
pN-M-6, pN-M-12, and pN-M-24, followed by collection of the cell supernatants. RNA 
was purified from the cell supernatants and subjected to reverse-transcription (RT)-PCR 
using specific primers. The resulting cDNAs were resolved by ethidium bromide-stained 
agarose gel electrophoresis. The cDNAs that represent gRNA purified from virus 
particles were present for all samples tested, but only in the samples that were treated 
with reverse-transcriptase during the first strand reaction (Fig. A1-4B). Furthermore, each 
fragment migrated to the predicted size (Fig. A1-4A, B). These results demonstrate that 
the MS2-binding site containing gRNAs were incorporated into virus particles. 
 
MS-2 gRNA localization is unaltered by the presence of MS2 binding sites 
 To determine whether MS2-site containing gRNA localization is altered by the 
presence of the MS2 binding sites, HeLa cells were transfected with pNL4-3, pNL4-3-  
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Figure A1-4. NL4-3-MS2 reporter RNAs are packaged into virus particles. 
(A) Schematic representation of RT-PCR strategy and expected fragment sizes. (B) HeLa 
cells were transfected with 3 µg of pNL43, pNL43-Rd4, pNL43-MS2-6, pNL43-MS2-12, 
or pNL43-MS2-24. At 48 hours post-transfection, cell supernatants were harvested and 
subjected to RNA purification. Purified RNA was subjected to reverse-transcription PCR. 
RT-PCR products (DNA) were resolved by gel electrophoresis and visualized by 
ethidium bromide staining. 
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Figure A1-5. NL4-3-MS2 reporter RNA localization. HeLa cells were transfected with 
2 ug of pNL4-3, pNL4-3-Rd4, pNL4-3-MS2-6, and pNL4-3-MS2-12 for 48 hours, 
followed by fixation. Cells were stained by fluorescence in situ hybridization using a 
Cy3-conjugated gag-pol probe and analyzed by fluorescence microscopy.  
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Rd4, pN-M-6, and pN-M-12 for 48 hours and fixed with paraformaldehyde. Cells were 
stained for RNA by fluorescence in situ hybridization using a Cy3-conjugated gag-pol 
DNA probe and were analyzed by fluorescence microscopy. MS2-site-containing gRNAs 
exhibited similar localization patterns as NL4-3 and NL4-3-Rd4 gRNAs, which 
demonstrates that the MS2 binding sites do not alter the intracellular localization of these 
gRNAs (Fig. A1-5).  
 
A1.3 Discussion 
 In this study, we generated three pNL4-3 constructs, pNL43-MS2-6, pNL43-
MS2-12, and pNL43-MS2-24, which contain 6, 12, or 24 MS2 binding sites in the 
integrase open reading frame, in order to specifically visualize genomic RNA in 
downstream applications. We demonstrated that the constructs could make virus 
particles, the resulting gRNA could be packaged into virus particles, and the resulting 
gRNA exhibited the same intracellular localization pattern as wild-type gRNA.  
 Although the virus particles could be generated by the expression of the 
constructs, the overall level of virus production was very low compared to the positive 
control, pNL4-3-Rd4. It is possible that ablation of the integrase open reading frame has 
contributed to the low replication efficiency of these constructs. However, it has been 
demonstrated that integrase-deleted HIV-1 molecular clones can be complemented in 
trans by expressing a Vpr-IN fusion protein (44). Future studies in which Vpr-IN is 
expressed in conjunction with the NL4-3-MS2 constructs that we generated would be 
warranted to determine whether virus production could be improved. In addition, further 
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studies could be performed to determine whether the incorporation of Vpr-IN into NL4-
3-MS2 virus particles could support integration, would enable future studies to be 
conducted by infection rather than transfection.  
 The other component of the MS2 reporter system is the MS2-GFP fusion protein. 
We were unable to successfully express the fusion protein with high efficiency by 
transient transfection. Attempts to generate a stable cell line were also unsuccessful, as 
the fusion protein exhibited cytotoxicity. Therefore, further optimization would be 
required in order to carry out downstream experiments involving the visualization of 
gRNA trafficking in living cells.  
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APPENDIX II: SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2-1. Optimization of AP-3δ-specific siRNA-mediated depletion of 
endogenous AP-3δ  in HeLa cells. (A) HeLa cells were either not transfected (NT) or 
transfected with siAP-3δ(2) (10, 50, 100 nM) and harvested at 24, 48, and 72 hours post-
transfection. Cell lysates were analyzed for protein expression by SDS-PAGE and 
Western blot, using anti-AP-3δ and anti-Sam68 antibodies. (B) HeLa cells were either 
not transfected (NT) or transfected with 0-100 nM of siAP-3δ(1) and harvested 48 hours 
post-transfection. Cell lysates were analyzed for protein expression by SDS-PAGE and 
Western blot, using anti-AP-3δ and anti-Sam68 antibodies.  
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Figure A2-2. Effect of hRIP depletion on HIV-1 production. (A) HeLa cells were 
transfected with reagent alone (Mock) or 50 nM hRIP-specific siRNA (sihRIP) for 48 
hours and infected with VSV-G/NL4-3Δenv (MOI = 0.25). At 48 hours post-infection, 
cell supernatants were analyzed by RT activity assay and cell lysates were analyzed by 
Western blot using anti-AP-3δ and anti-hRIP antibodies. (B) MDM cells were transfected 
with reagent alone (Mock) or 50 nM hRIP-specific siRNA (sihRIP) for 48 hours and 
infected with VSV-G/NL4-3Δenv (MOI = 1.0. At 5 days post-infection, cell supernatants 
were analyzed by RT activity assay and cell lysates were analyzed by SDS-PAGE and 
Western blot using anti-AP-3δ and anti-hRIP antibodies.   
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Figure A2-3. Depletion of AP-3δ  with a panel of AP-3δ-specific siRNAs. HeLa cells 
were transfected with reagent alone (Mock, M) or 50 nM individually with siAP-3δ(1)-
(5). At 48 hours post-transfection, cells were harvested. Cell lysates were analyzed for 
protein expression by SDS-PAGE and Western blot using anti-AP-3δ and Sam68 
antibodies. 
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Figure  A2-4. Effect of siRNA concentration on AP-3δ  expression. HeLa cells were 
transfected with 1 nM, 10 nM, and 100 nM of siANC or individually with siAP-3δ(1)-
(5). At 48 hours post-transfection, cells were harvested and subsequently lysed. Cell 
lysates were analyzed by SDS-PAGE and Western blot with anti-AP-3δ, and Sam68 
antibodies.   
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